# PeptideScanner evidence objects: Icatibant

Every published version of the records placed with Icatibant, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/icatibant.json. Selected public evidence only; not medical advice.

- Objects: 64
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00097695-icatibant-v1"></a>

## ClinicalTrials.gov record NCT00097695

> PeptideScanner retained ClinicalTrials.gov record NCT00097695 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct00097695-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00097695-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct00097695-icatibant-v1
- Content SHA-256: `806d64ecba11170b07e8c00ef99aa7741ba7264f01490526036a6dbe52c4923d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00097695 ([`ctg-observation-nct00097695-2021-06-09-322c7095ae8c`](#source-ctg-observation-nct00097695-2021-06-09-322c7095ae8c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00097695 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct00097695-2021-06-09-322c7095ae8c`](#source-ctg-observation-nct00097695-2021-06-09-322c7095ae8c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00097695 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct00097695-2021-06-09-322c7095ae8c`](#source-ctg-observation-nct00097695-2021-06-09-322c7095ae8c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00097695-2021-06-09-322c7095ae8c`](#source-ctg-observation-nct00097695-2021-06-09-322c7095ae8c))

### Sources

<a id="source-ctg-observation-nct00097695-2021-06-09-322c7095ae8c"></a>
- **ClinicalTrials.gov record NCT00097695 · retained source version 2021-06-09:322c7095ae8cf9110533868496b748ba2d0ad0cdb64cd9956970ff0923f0c0c9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00097695) (`ctg-observation-nct00097695-2021-06-09-322c7095ae8c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00097695." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct00097695-icatibant-v1 SHA-256: 806d64ecba11170b07e8c00ef99aa7741ba7264f01490526036a6dbe52c4923d.

---

<a id="clinicaltrials-gov-nct00223704-icatibant-v1"></a>

## ClinicalTrials.gov record NCT00223704

> PeptideScanner retained ClinicalTrials.gov record NCT00223704 at 2026-11-15T22:04:12.435Z. Its registry update date was 2013-11-25, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct00223704-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-11-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00223704-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct00223704-icatibant-v1
- Content SHA-256: `b2526670d40d2e6a7ddb26a663f6a2e64d4371b938d9ea8f9fc30e6c87bf2b3e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00223704 ([`ctg-observation-nct00223704-2013-11-25-12d79c801a2a`](#source-ctg-observation-nct00223704-2013-11-25-12d79c801a2a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00223704 at 2026-11-15T22:04:12.435Z. Its registry update date was 2013-11-25, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct00223704-2013-11-25-12d79c801a2a`](#source-ctg-observation-nct00223704-2013-11-25-12d79c801a2a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00223704 at 2026-11-15T22:04:12.435Z. Its registry update date was 2013-11-25, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct00223704-2013-11-25-12d79c801a2a`](#source-ctg-observation-nct00223704-2013-11-25-12d79c801a2a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00223704-2013-11-25-12d79c801a2a`](#source-ctg-observation-nct00223704-2013-11-25-12d79c801a2a))

### Sources

<a id="source-ctg-observation-nct00223704-2013-11-25-12d79c801a2a"></a>
- **ClinicalTrials.gov record NCT00223704 · retained source version 2013-11-25:12d79c801a2a1edda50debd15ebdcec381bca0d2b06216eef4219b83331aba08** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00223704) (`ctg-observation-nct00223704-2013-11-25-12d79c801a2a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00223704." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct00223704-icatibant-v1 SHA-256: b2526670d40d2e6a7ddb26a663f6a2e64d4371b938d9ea8f9fc30e6c87bf2b3e.

---

<a id="clinicaltrials-gov-nct00500656-icatibant-v1"></a>

## ClinicalTrials.gov record NCT00500656

> PeptideScanner retained ClinicalTrials.gov record NCT00500656 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct00500656-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00500656-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct00500656-icatibant-v1
- Content SHA-256: `6581d62bf29baa08180c9aeb8a1ed57d4aa4a50c161db89da47f528a831d1ce8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00500656 ([`ctg-observation-nct00500656-2021-06-09-233c45d7c58c`](#source-ctg-observation-nct00500656-2021-06-09-233c45d7c58c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00500656 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct00500656-2021-06-09-233c45d7c58c`](#source-ctg-observation-nct00500656-2021-06-09-233c45d7c58c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00500656 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct00500656-2021-06-09-233c45d7c58c`](#source-ctg-observation-nct00500656-2021-06-09-233c45d7c58c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00500656-2021-06-09-233c45d7c58c`](#source-ctg-observation-nct00500656-2021-06-09-233c45d7c58c))

### Sources

<a id="source-ctg-observation-nct00500656-2021-06-09-233c45d7c58c"></a>
- **ClinicalTrials.gov record NCT00500656 · retained source version 2021-06-09:233c45d7c58c59abf54946a057c839b963b52eabbb2fe14fffd0d5c8892c8a31** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00500656) (`ctg-observation-nct00500656-2021-06-09-233c45d7c58c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00500656." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct00500656-icatibant-v1 SHA-256: 6581d62bf29baa08180c9aeb8a1ed57d4aa4a50c161db89da47f528a831d1ce8.

---

<a id="clinicaltrials-gov-nct00912093-icatibant-v1"></a>

## ClinicalTrials.gov record NCT00912093

> PeptideScanner retained ClinicalTrials.gov record NCT00912093 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct00912093-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00912093-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct00912093-icatibant-v1
- Content SHA-256: `d3431b11ed94dc66289b9e329ce1b4146fed98b78e757e5e1b414e8f60f5a680`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00912093 ([`ctg-observation-nct00912093-2021-06-11-4225022c7d13`](#source-ctg-observation-nct00912093-2021-06-11-4225022c7d13))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00912093 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct00912093-2021-06-11-4225022c7d13`](#source-ctg-observation-nct00912093-2021-06-11-4225022c7d13))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00912093 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct00912093-2021-06-11-4225022c7d13`](#source-ctg-observation-nct00912093-2021-06-11-4225022c7d13))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00912093-2021-06-11-4225022c7d13`](#source-ctg-observation-nct00912093-2021-06-11-4225022c7d13))

### Sources

<a id="source-ctg-observation-nct00912093-2021-06-11-4225022c7d13"></a>
- **ClinicalTrials.gov record NCT00912093 · retained source version 2021-06-11:4225022c7d136e0b51fc6c08ed205ae1631dbca23cc1dea9d11daf76ff931004** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00912093) (`ctg-observation-nct00912093-2021-06-11-4225022c7d13`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00912093." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct00912093-icatibant-v1 SHA-256: d3431b11ed94dc66289b9e329ce1b4146fed98b78e757e5e1b414e8f60f5a680.

---

<a id="clinicaltrials-gov-nct00997204-icatibant-v1"></a>

## ClinicalTrials.gov record NCT00997204

> PeptideScanner retained ClinicalTrials.gov record NCT00997204 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct00997204-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00997204-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct00997204-icatibant-v1
- Content SHA-256: `e6942bfa55b531de49a39a8bc9e93469ee8840975ac0cd467bc3a77459448118`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00997204 ([`ctg-observation-nct00997204-2021-06-11-d66ee7250b8a`](#source-ctg-observation-nct00997204-2021-06-11-d66ee7250b8a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00997204 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct00997204-2021-06-11-d66ee7250b8a`](#source-ctg-observation-nct00997204-2021-06-11-d66ee7250b8a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00997204 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct00997204-2021-06-11-d66ee7250b8a`](#source-ctg-observation-nct00997204-2021-06-11-d66ee7250b8a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00997204-2021-06-11-d66ee7250b8a`](#source-ctg-observation-nct00997204-2021-06-11-d66ee7250b8a))

### Sources

<a id="source-ctg-observation-nct00997204-2021-06-11-d66ee7250b8a"></a>
- **ClinicalTrials.gov record NCT00997204 · retained source version 2021-06-11:d66ee7250b8aea79f23e16070f1d3f39a5b087a0730cd89bf8fe44b8f2b45c29** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00997204) (`ctg-observation-nct00997204-2021-06-11-d66ee7250b8a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00997204." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct00997204-icatibant-v1 SHA-256: e6942bfa55b531de49a39a8bc9e93469ee8840975ac0cd467bc3a77459448118.

---

<a id="clinicaltrials-gov-nct01386658-icatibant-v1"></a>

## ClinicalTrials.gov record NCT01386658

> PeptideScanner retained ClinicalTrials.gov record NCT01386658 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-08, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct01386658-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01386658-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct01386658-icatibant-v1
- Content SHA-256: `6b83c361ccb29dc558c7de4cbed35af451b58f21ff3c8d4533bff88201d71694`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01386658 ([`ctg-observation-nct01386658-2021-06-08-e301b064adcc`](#source-ctg-observation-nct01386658-2021-06-08-e301b064adcc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01386658 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-08, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct01386658-2021-06-08-e301b064adcc`](#source-ctg-observation-nct01386658-2021-06-08-e301b064adcc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01386658 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-08, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct01386658-2021-06-08-e301b064adcc`](#source-ctg-observation-nct01386658-2021-06-08-e301b064adcc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01386658-2021-06-08-e301b064adcc`](#source-ctg-observation-nct01386658-2021-06-08-e301b064adcc))

### Sources

<a id="source-ctg-observation-nct01386658-2021-06-08-e301b064adcc"></a>
- **ClinicalTrials.gov record NCT01386658 · retained source version 2021-06-08:e301b064adccfa037772d850449f35564deb33fbd3d39710e94cc29d420db06e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01386658) (`ctg-observation-nct01386658-2021-06-08-e301b064adcc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01386658." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct01386658-icatibant-v1 SHA-256: 6b83c361ccb29dc558c7de4cbed35af451b58f21ff3c8d4533bff88201d71694.

---

<a id="clinicaltrials-gov-nct01457430-icatibant-v1"></a>

## ClinicalTrials.gov record NCT01457430

> PeptideScanner retained ClinicalTrials.gov record NCT01457430 at 2026-11-15T22:04:12.435Z. Its registry update date was 2016-10-18, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct01457430-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-10-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01457430-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct01457430-icatibant-v1
- Content SHA-256: `6e0f74a0dd3a20708c51b62c85bffbba130ae1087fcd9b226f92c1a753241dae`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01457430 ([`ctg-observation-nct01457430-2016-10-18-a9bb9bd35fee`](#source-ctg-observation-nct01457430-2016-10-18-a9bb9bd35fee))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01457430 at 2026-11-15T22:04:12.435Z. Its registry update date was 2016-10-18, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct01457430-2016-10-18-a9bb9bd35fee`](#source-ctg-observation-nct01457430-2016-10-18-a9bb9bd35fee))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01457430 at 2026-11-15T22:04:12.435Z. Its registry update date was 2016-10-18, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct01457430-2016-10-18-a9bb9bd35fee`](#source-ctg-observation-nct01457430-2016-10-18-a9bb9bd35fee))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01457430-2016-10-18-a9bb9bd35fee`](#source-ctg-observation-nct01457430-2016-10-18-a9bb9bd35fee))

### Sources

<a id="source-ctg-observation-nct01457430-2016-10-18-a9bb9bd35fee"></a>
- **ClinicalTrials.gov record NCT01457430 · retained source version 2016-10-18:a9bb9bd35fee5b49b145be34d1ff0f1e428265c83923932256b2fc6c2261cca9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01457430) (`ctg-observation-nct01457430-2016-10-18-a9bb9bd35fee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01457430." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct01457430-icatibant-v1 SHA-256: 6e0f74a0dd3a20708c51b62c85bffbba130ae1087fcd9b226f92c1a753241dae.

---

<a id="clinicaltrials-gov-nct01919801-icatibant-v1"></a>

## ClinicalTrials.gov record NCT01919801

> PeptideScanner retained ClinicalTrials.gov record NCT01919801 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-08, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct01919801-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01919801-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct01919801-icatibant-v1
- Content SHA-256: `c8924ccecea6d12b3f9ba129a4880b4248a73b66154a880de37f09c69dfee593`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01919801 ([`ctg-observation-nct01919801-2021-06-08-3dc654b46b9e`](#source-ctg-observation-nct01919801-2021-06-08-3dc654b46b9e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01919801 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-08, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct01919801-2021-06-08-3dc654b46b9e`](#source-ctg-observation-nct01919801-2021-06-08-3dc654b46b9e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01919801 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-08, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct01919801-2021-06-08-3dc654b46b9e`](#source-ctg-observation-nct01919801-2021-06-08-3dc654b46b9e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01919801-2021-06-08-3dc654b46b9e`](#source-ctg-observation-nct01919801-2021-06-08-3dc654b46b9e))

### Sources

<a id="source-ctg-observation-nct01919801-2021-06-08-3dc654b46b9e"></a>
- **ClinicalTrials.gov record NCT01919801 · retained source version 2021-06-08:3dc654b46b9e086406bc5c44a1aac1411a23eb6f46032b59c13c463c0f001099** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01919801) (`ctg-observation-nct01919801-2021-06-08-3dc654b46b9e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01919801." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct01919801-icatibant-v1 SHA-256: c8924ccecea6d12b3f9ba129a4880b4248a73b66154a880de37f09c69dfee593.

---

<a id="clinicaltrials-gov-nct02045264-icatibant-v1"></a>

## ClinicalTrials.gov record NCT02045264

> PeptideScanner retained ClinicalTrials.gov record NCT02045264 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct02045264-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02045264-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct02045264-icatibant-v1
- Content SHA-256: `2655211de371a49d282d299474e04c4117013811b45918022ac6a1892c7d90e4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02045264 ([`ctg-observation-nct02045264-2021-06-03-988c25d7292a`](#source-ctg-observation-nct02045264-2021-06-03-988c25d7292a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02045264 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct02045264-2021-06-03-988c25d7292a`](#source-ctg-observation-nct02045264-2021-06-03-988c25d7292a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02045264 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct02045264-2021-06-03-988c25d7292a`](#source-ctg-observation-nct02045264-2021-06-03-988c25d7292a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02045264-2021-06-03-988c25d7292a`](#source-ctg-observation-nct02045264-2021-06-03-988c25d7292a))

### Sources

<a id="source-ctg-observation-nct02045264-2021-06-03-988c25d7292a"></a>
- **ClinicalTrials.gov record NCT02045264 · retained source version 2021-06-03:988c25d7292afdf4edc1d502f55fd5ea2fca1b80af684e8c02aa65a372a3fdf9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02045264) (`ctg-observation-nct02045264-2021-06-03-988c25d7292a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02045264." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct02045264-icatibant-v1 SHA-256: 2655211de371a49d282d299474e04c4117013811b45918022ac6a1892c7d90e4.

---

<a id="clinicaltrials-gov-nct03177798-icatibant-v1"></a>

## ClinicalTrials.gov record NCT03177798

> PeptideScanner retained ClinicalTrials.gov record NCT03177798 at 2026-11-15T22:04:12.435Z. Its registry update date was 2019-10-29, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct03177798-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-10-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03177798-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct03177798-icatibant-v1
- Content SHA-256: `d94392dd3d781f84d1629d182a5abc519da7bb2acd22fa25b7edb0eee9eea5fc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03177798 ([`ctg-observation-nct03177798-2019-10-29-6600b7ba7533`](#source-ctg-observation-nct03177798-2019-10-29-6600b7ba7533))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03177798 at 2026-11-15T22:04:12.435Z. Its registry update date was 2019-10-29, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct03177798-2019-10-29-6600b7ba7533`](#source-ctg-observation-nct03177798-2019-10-29-6600b7ba7533))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03177798 at 2026-11-15T22:04:12.435Z. Its registry update date was 2019-10-29, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct03177798-2019-10-29-6600b7ba7533`](#source-ctg-observation-nct03177798-2019-10-29-6600b7ba7533))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03177798-2019-10-29-6600b7ba7533`](#source-ctg-observation-nct03177798-2019-10-29-6600b7ba7533))

### Sources

<a id="source-ctg-observation-nct03177798-2019-10-29-6600b7ba7533"></a>
- **ClinicalTrials.gov record NCT03177798 · retained source version 2019-10-29:6600b7ba753373ae71549ce1585fd0cd38da28751f60f1e0a48542816f60635a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03177798) (`ctg-observation-nct03177798-2019-10-29-6600b7ba7533`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03177798." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct03177798-icatibant-v1 SHA-256: d94392dd3d781f84d1629d182a5abc519da7bb2acd22fa25b7edb0eee9eea5fc.

---

<a id="clinicaltrials-gov-nct03888755-icatibant-v1"></a>

## ClinicalTrials.gov record NCT03888755

> PeptideScanner retained ClinicalTrials.gov record NCT03888755 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct03888755-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03888755-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct03888755-icatibant-v1
- Content SHA-256: `dfe93d7f190cf3e3259524eb0770dd1c55cc79c412254df449768ad3ceae93dc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03888755 ([`ctg-observation-nct03888755-2021-06-03-007a112b45a1`](#source-ctg-observation-nct03888755-2021-06-03-007a112b45a1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03888755 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct03888755-2021-06-03-007a112b45a1`](#source-ctg-observation-nct03888755-2021-06-03-007a112b45a1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03888755 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct03888755-2021-06-03-007a112b45a1`](#source-ctg-observation-nct03888755-2021-06-03-007a112b45a1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03888755-2021-06-03-007a112b45a1`](#source-ctg-observation-nct03888755-2021-06-03-007a112b45a1))

### Sources

<a id="source-ctg-observation-nct03888755-2021-06-03-007a112b45a1"></a>
- **ClinicalTrials.gov record NCT03888755 · retained source version 2021-06-03:007a112b45a15f8bf8c4fb45fd89b991a5bc93b50e0dbcefc9dac279d3fe4282** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03888755) (`ctg-observation-nct03888755-2021-06-03-007a112b45a1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03888755." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct03888755-icatibant-v1 SHA-256: dfe93d7f190cf3e3259524eb0770dd1c55cc79c412254df449768ad3ceae93dc.

---

<a id="clinicaltrials-gov-nct04057131-icatibant-v1"></a>

## ClinicalTrials.gov record NCT04057131

> PeptideScanner retained ClinicalTrials.gov record NCT04057131 at 2026-11-15T22:04:12.435Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct04057131-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-02-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04057131-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct04057131-icatibant-v1
- Content SHA-256: `92b245bcaf091e266036312cdb433f44b025d19b342a877cdad598b7b48be9d8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04057131 ([`ctg-observation-nct04057131-2025-02-21-8f2896533f8f`](#source-ctg-observation-nct04057131-2025-02-21-8f2896533f8f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04057131 at 2026-11-15T22:04:12.435Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct04057131-2025-02-21-8f2896533f8f`](#source-ctg-observation-nct04057131-2025-02-21-8f2896533f8f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04057131 at 2026-11-15T22:04:12.435Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct04057131-2025-02-21-8f2896533f8f`](#source-ctg-observation-nct04057131-2025-02-21-8f2896533f8f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04057131-2025-02-21-8f2896533f8f`](#source-ctg-observation-nct04057131-2025-02-21-8f2896533f8f))

### Sources

<a id="source-ctg-observation-nct04057131-2025-02-21-8f2896533f8f"></a>
- **ClinicalTrials.gov record NCT04057131 · retained source version 2025-02-21:8f2896533f8fc9ef404374349db9cd8d547a473cfe9aabfd3be33e06469d460a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04057131) (`ctg-observation-nct04057131-2025-02-21-8f2896533f8f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04057131." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct04057131-icatibant-v1 SHA-256: 92b245bcaf091e266036312cdb433f44b025d19b342a877cdad598b7b48be9d8.

---

<a id="clinicaltrials-gov-nct04113109-icatibant-v1"></a>

## ClinicalTrials.gov record NCT04113109

> PeptideScanner retained ClinicalTrials.gov record NCT04113109 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct04113109-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04113109-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct04113109-icatibant-v1
- Content SHA-256: `9acd1f29f810621845592ccd436e16ba38e26642e79ebed56923e735ea6eb22b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04113109 ([`ctg-observation-nct04113109-2026-08-11-602ebdebab4a`](#source-ctg-observation-nct04113109-2026-08-11-602ebdebab4a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04113109 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct04113109-2026-08-11-602ebdebab4a`](#source-ctg-observation-nct04113109-2026-08-11-602ebdebab4a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04113109 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct04113109-2026-08-11-602ebdebab4a`](#source-ctg-observation-nct04113109-2026-08-11-602ebdebab4a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04113109-2026-08-11-602ebdebab4a`](#source-ctg-observation-nct04113109-2026-08-11-602ebdebab4a))

### Sources

<a id="source-ctg-observation-nct04113109-2026-08-11-602ebdebab4a"></a>
- **ClinicalTrials.gov record NCT04113109 · retained source version 2026-08-11:602ebdebab4add3e207d35e49946006fa3c67b6f4d094ca47762063ba90e2f28** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04113109) (`ctg-observation-nct04113109-2026-08-11-602ebdebab4a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04113109." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct04113109-icatibant-v1 SHA-256: 9acd1f29f810621845592ccd436e16ba38e26642e79ebed56923e735ea6eb22b.

---

<a id="clinicaltrials-gov-nct04488081-icatibant-v1"></a>

## ClinicalTrials.gov record NCT04488081

> PeptideScanner retained ClinicalTrials.gov record NCT04488081 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-03-16, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct04488081-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04488081-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct04488081-icatibant-v1
- Content SHA-256: `f66c73bb47953c37c664f0bd0fab8027a9dcb9e82344dc78363fe7445bdc8391`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04488081 ([`ctg-observation-nct04488081-2026-03-16-07156c1a6cf4`](#source-ctg-observation-nct04488081-2026-03-16-07156c1a6cf4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04488081 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-03-16, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct04488081-2026-03-16-07156c1a6cf4`](#source-ctg-observation-nct04488081-2026-03-16-07156c1a6cf4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04488081 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-03-16, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct04488081-2026-03-16-07156c1a6cf4`](#source-ctg-observation-nct04488081-2026-03-16-07156c1a6cf4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04488081-2026-03-16-07156c1a6cf4`](#source-ctg-observation-nct04488081-2026-03-16-07156c1a6cf4))

### Sources

<a id="source-ctg-observation-nct04488081-2026-03-16-07156c1a6cf4"></a>
- **ClinicalTrials.gov record NCT04488081 · retained source version 2026-03-16:07156c1a6cf4d097180ab48b338786ebfdaa31500ed5107b87bba233a41a0ee0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04488081) (`ctg-observation-nct04488081-2026-03-16-07156c1a6cf4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04488081." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct04488081-icatibant-v1 SHA-256: f66c73bb47953c37c664f0bd0fab8027a9dcb9e82344dc78363fe7445bdc8391.

---

<a id="clinicaltrials-gov-nct04654351-icatibant-v1"></a>

## ClinicalTrials.gov record NCT04654351

> PeptideScanner retained ClinicalTrials.gov record NCT04654351 at 2026-11-15T22:04:12.435Z. Its registry update date was 2022-03-29, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct04654351-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-03-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04654351-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct04654351-icatibant-v1
- Content SHA-256: `0d972a16e45ccd50134a0642b84f7539a8da59359e270f7d6e6403c1c2c79062`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04654351 ([`ctg-observation-nct04654351-2022-03-29-9c7c9a36f67c`](#source-ctg-observation-nct04654351-2022-03-29-9c7c9a36f67c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04654351 at 2026-11-15T22:04:12.435Z. Its registry update date was 2022-03-29, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct04654351-2022-03-29-9c7c9a36f67c`](#source-ctg-observation-nct04654351-2022-03-29-9c7c9a36f67c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04654351 at 2026-11-15T22:04:12.435Z. Its registry update date was 2022-03-29, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct04654351-2022-03-29-9c7c9a36f67c`](#source-ctg-observation-nct04654351-2022-03-29-9c7c9a36f67c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04654351-2022-03-29-9c7c9a36f67c`](#source-ctg-observation-nct04654351-2022-03-29-9c7c9a36f67c))

### Sources

<a id="source-ctg-observation-nct04654351-2022-03-29-9c7c9a36f67c"></a>
- **ClinicalTrials.gov record NCT04654351 · retained source version 2022-03-29:9c7c9a36f67c6a2f45302f75068d0e68220a832b68dffcf41931953ff8af97e0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04654351) (`ctg-observation-nct04654351-2022-03-29-9c7c9a36f67c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04654351." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct04654351-icatibant-v1 SHA-256: 0d972a16e45ccd50134a0642b84f7539a8da59359e270f7d6e6403c1c2c79062.

---

<a id="clinicaltrials-gov-nct04978051-icatibant-v1"></a>

## ClinicalTrials.gov record NCT04978051

> PeptideScanner retained ClinicalTrials.gov record NCT04978051 at 2026-11-15T22:04:12.435Z. Its registry update date was 2022-08-03, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct04978051-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-08-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04978051-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct04978051-icatibant-v1
- Content SHA-256: `4b67d46afa3d5426665ed9277934130cbf3e887d34d0e0437f803ea054f2efe1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04978051 ([`ctg-observation-nct04978051-2022-08-03-babf1ad8edf1`](#source-ctg-observation-nct04978051-2022-08-03-babf1ad8edf1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04978051 at 2026-11-15T22:04:12.435Z. Its registry update date was 2022-08-03, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct04978051-2022-08-03-babf1ad8edf1`](#source-ctg-observation-nct04978051-2022-08-03-babf1ad8edf1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04978051 at 2026-11-15T22:04:12.435Z. Its registry update date was 2022-08-03, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct04978051-2022-08-03-babf1ad8edf1`](#source-ctg-observation-nct04978051-2022-08-03-babf1ad8edf1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04978051-2022-08-03-babf1ad8edf1`](#source-ctg-observation-nct04978051-2022-08-03-babf1ad8edf1))

### Sources

<a id="source-ctg-observation-nct04978051-2022-08-03-babf1ad8edf1"></a>
- **ClinicalTrials.gov record NCT04978051 · retained source version 2022-08-03:babf1ad8edf12b9aadbd1b361d5973a19ee9bbadc2c9f6e45dd78cacd2424e86** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04978051) (`ctg-observation-nct04978051-2022-08-03-babf1ad8edf1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04978051." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct04978051-icatibant-v1 SHA-256: 4b67d46afa3d5426665ed9277934130cbf3e887d34d0e0437f803ea054f2efe1.

---

<a id="clinicaltrials-gov-nct05407597-icatibant-v1"></a>

## ClinicalTrials.gov record NCT05407597

> PeptideScanner retained ClinicalTrials.gov record NCT05407597 at 2026-11-15T22:04:12.435Z. Its registry update date was 2023-09-07, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct05407597-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-09-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05407597-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct05407597-icatibant-v1
- Content SHA-256: `7a991dda4af012f101a1b9e82f29a20647ad7bfc40acc3194476c98f31d5a179`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05407597 ([`ctg-observation-nct05407597-2023-09-07-2af9903ef7b5`](#source-ctg-observation-nct05407597-2023-09-07-2af9903ef7b5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05407597 at 2026-11-15T22:04:12.435Z. Its registry update date was 2023-09-07, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct05407597-2023-09-07-2af9903ef7b5`](#source-ctg-observation-nct05407597-2023-09-07-2af9903ef7b5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05407597 at 2026-11-15T22:04:12.435Z. Its registry update date was 2023-09-07, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct05407597-2023-09-07-2af9903ef7b5`](#source-ctg-observation-nct05407597-2023-09-07-2af9903ef7b5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05407597-2023-09-07-2af9903ef7b5`](#source-ctg-observation-nct05407597-2023-09-07-2af9903ef7b5))

### Sources

<a id="source-ctg-observation-nct05407597-2023-09-07-2af9903ef7b5"></a>
- **ClinicalTrials.gov record NCT05407597 · retained source version 2023-09-07:2af9903ef7b5341f88e66402d8d80c00b5684f2951cdda8540d15d198b2a50b0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05407597) (`ctg-observation-nct05407597-2023-09-07-2af9903ef7b5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05407597." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct05407597-icatibant-v1 SHA-256: 7a991dda4af012f101a1b9e82f29a20647ad7bfc40acc3194476c98f31d5a179.

---

<a id="clinicaltrials-gov-nct05509569-icatibant-v1"></a>

## ClinicalTrials.gov record NCT05509569

> PeptideScanner retained ClinicalTrials.gov record NCT05509569 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct05509569-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05509569-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct05509569-icatibant-v1
- Content SHA-256: `ac60b4e8c593f01a9a13859dcb798d91ef67c2a4ea18f5f318fe53d427b26007`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05509569 ([`ctg-observation-nct05509569-2026-08-07-7a266e9e5303`](#source-ctg-observation-nct05509569-2026-08-07-7a266e9e5303))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05509569 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct05509569-2026-08-07-7a266e9e5303`](#source-ctg-observation-nct05509569-2026-08-07-7a266e9e5303))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05509569 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct05509569-2026-08-07-7a266e9e5303`](#source-ctg-observation-nct05509569-2026-08-07-7a266e9e5303))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05509569-2026-08-07-7a266e9e5303`](#source-ctg-observation-nct05509569-2026-08-07-7a266e9e5303))

### Sources

<a id="source-ctg-observation-nct05509569-2026-08-07-7a266e9e5303"></a>
- **ClinicalTrials.gov record NCT05509569 · retained source version 2026-08-07:7a266e9e530303281b78fb8f2b4f0315ad3fc6a059e4db0c890e42f0d4ded639** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05509569) (`ctg-observation-nct05509569-2026-08-07-7a266e9e5303`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05509569." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct05509569-icatibant-v1 SHA-256: ac60b4e8c593f01a9a13859dcb798d91ef67c2a4ea18f5f318fe53d427b26007.

---

<a id="clinicaltrials-gov-nct05834777-icatibant-v1"></a>

## ClinicalTrials.gov record NCT05834777

> PeptideScanner retained ClinicalTrials.gov record NCT05834777 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was icatibant.

- Evidence object: `story:clinicaltrials-gov-nct05834777-icatibant:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05834777-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct05834777-icatibant-v1
- Content SHA-256: `8231339b37e2bd18bc31fa9611a049642cd541821903cb23abb180da8ec9afbb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05834777 ([`ctg-observation-nct05834777-2026-10-22-c1ebe3cbbb2c`](#source-ctg-observation-nct05834777-2026-10-22-c1ebe3cbbb2c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05834777 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct05834777-2026-10-22-c1ebe3cbbb2c`](#source-ctg-observation-nct05834777-2026-10-22-c1ebe3cbbb2c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05834777 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was icatibant. ([`ctg-observation-nct05834777-2026-10-22-c1ebe3cbbb2c`](#source-ctg-observation-nct05834777-2026-10-22-c1ebe3cbbb2c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05834777-2026-10-22-c1ebe3cbbb2c`](#source-ctg-observation-nct05834777-2026-10-22-c1ebe3cbbb2c))

### Sources

<a id="source-ctg-observation-nct05834777-2026-10-22-c1ebe3cbbb2c"></a>
- **ClinicalTrials.gov record NCT05834777 · retained source version 2026-10-22:c1ebe3cbbb2c16a17c73e1bdaf3400da704ced061a6e391ca3e631311eda0c10** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05834777) (`ctg-observation-nct05834777-2026-10-22-c1ebe3cbbb2c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05834777." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#clinicaltrials-gov-nct05834777-icatibant-v1 SHA-256: 8231339b37e2bd18bc31fa9611a049642cd541821903cb23abb180da8ec9afbb.

---

<a id="fda-drugs-anda208317-v1"></a>

## Drugs@FDA application ANDA208317

> The official Drugs@FDA dataset lists original submission 1 for ANDA 208317 with status AP dated 2020-06-18, and names icatibant acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda208317:v1`
- Evidence domain: Regulatory
- Date in source: 2020-06-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda208317/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda208317-v1
- Content SHA-256: `bbd2783e77fa453441044779a2b929949017b669c3e5c452fcf0ac84c9ac5095`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA208317 ([`fda-drugs-anda208317-2020-06-18-2f898c7aea0f`](#source-fda-drugs-anda208317-2020-06-18-2f898c7aea0f))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 208317 with status AP dated 2020-06-18, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda208317-2020-06-18-2f898c7aea0f`](#source-fda-drugs-anda208317-2020-06-18-2f898c7aea0f))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 208317 with status AP dated 2020-06-18, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda208317-2020-06-18-2f898c7aea0f`](#source-fda-drugs-anda208317-2020-06-18-2f898c7aea0f))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda208317-2020-06-18-2f898c7aea0f`](#source-fda-drugs-anda208317-2020-06-18-2f898c7aea0f))

### Sources

<a id="source-fda-drugs-anda208317-2020-06-18-2f898c7aea0f"></a>
- **Drugs@FDA application ANDA208317 · original submission status AP · 2020-06-18 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA208317%22&limit=1) (`fda-drugs-anda208317-2020-06-18-2f898c7aea0f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA208317." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda208317-v1 SHA-256: bbd2783e77fa453441044779a2b929949017b669c3e5c452fcf0ac84c9ac5095.

---

<a id="fda-drugs-anda210118-v1"></a>

## Drugs@FDA application ANDA210118

> The official Drugs@FDA dataset lists original submission 1 for ANDA 210118 with status AP dated 2019-07-15, and names icatibant acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda210118:v1`
- Evidence domain: Regulatory
- Date in source: 2019-07-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda210118/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda210118-v1
- Content SHA-256: `0168643d2066c3471de88f35c5c04de89d533b3347ba79dd3c53efd002705ca1`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA210118 ([`fda-drugs-anda210118-2019-07-15-73fd0eb1da01`](#source-fda-drugs-anda210118-2019-07-15-73fd0eb1da01))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 210118 with status AP dated 2019-07-15, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda210118-2019-07-15-73fd0eb1da01`](#source-fda-drugs-anda210118-2019-07-15-73fd0eb1da01))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 210118 with status AP dated 2019-07-15, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda210118-2019-07-15-73fd0eb1da01`](#source-fda-drugs-anda210118-2019-07-15-73fd0eb1da01))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda210118-2019-07-15-73fd0eb1da01`](#source-fda-drugs-anda210118-2019-07-15-73fd0eb1da01))

### Sources

<a id="source-fda-drugs-anda210118-2019-07-15-73fd0eb1da01"></a>
- **Drugs@FDA application ANDA210118 · original submission status AP · 2019-07-15 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA210118%22&limit=1) (`fda-drugs-anda210118-2019-07-15-73fd0eb1da01`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA210118." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda210118-v1 SHA-256: 0168643d2066c3471de88f35c5c04de89d533b3347ba79dd3c53efd002705ca1.

---

<a id="fda-drugs-anda211021-v1"></a>

## Drugs@FDA application ANDA211021

> The official Drugs@FDA dataset lists original submission 1 for ANDA 211021 with status AP dated 2020-03-09, and names icatibant acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda211021:v1`
- Evidence domain: Regulatory
- Date in source: 2020-03-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda211021/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda211021-v1
- Content SHA-256: `291519116de9000d1cde853bd98a7eead0b94544c583db46ea4964ed6b95cca2`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA211021 ([`fda-drugs-anda211021-2020-03-09-5e3898902004`](#source-fda-drugs-anda211021-2020-03-09-5e3898902004))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 211021 with status AP dated 2020-03-09, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda211021-2020-03-09-5e3898902004`](#source-fda-drugs-anda211021-2020-03-09-5e3898902004))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 211021 with status AP dated 2020-03-09, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda211021-2020-03-09-5e3898902004`](#source-fda-drugs-anda211021-2020-03-09-5e3898902004))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda211021-2020-03-09-5e3898902004`](#source-fda-drugs-anda211021-2020-03-09-5e3898902004))

### Sources

<a id="source-fda-drugs-anda211021-2020-03-09-5e3898902004"></a>
- **Drugs@FDA application ANDA211021 · original submission status AP · 2020-03-09 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA211021%22&limit=1) (`fda-drugs-anda211021-2020-03-09-5e3898902004`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA211021." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda211021-v1 SHA-256: 291519116de9000d1cde853bd98a7eead0b94544c583db46ea4964ed6b95cca2.

---

<a id="fda-drugs-anda211501-v1"></a>

## Drugs@FDA application ANDA211501

> The official Drugs@FDA dataset lists original submission 1 for ANDA 211501 with status AP dated 2020-09-02, and names icatibant acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda211501:v1`
- Evidence domain: Regulatory
- Date in source: 2020-09-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda211501/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda211501-v1
- Content SHA-256: `03f0220a45389fd204ca9e1b1f95fc9dbd5a46ef55ef8f8116eb6c25c9b66512`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA211501 ([`fda-drugs-anda211501-2020-09-02-b0b6bb168ed0`](#source-fda-drugs-anda211501-2020-09-02-b0b6bb168ed0))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 211501 with status AP dated 2020-09-02, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda211501-2020-09-02-b0b6bb168ed0`](#source-fda-drugs-anda211501-2020-09-02-b0b6bb168ed0))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 211501 with status AP dated 2020-09-02, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda211501-2020-09-02-b0b6bb168ed0`](#source-fda-drugs-anda211501-2020-09-02-b0b6bb168ed0))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda211501-2020-09-02-b0b6bb168ed0`](#source-fda-drugs-anda211501-2020-09-02-b0b6bb168ed0))

### Sources

<a id="source-fda-drugs-anda211501-2020-09-02-b0b6bb168ed0"></a>
- **Drugs@FDA application ANDA211501 · original submission status AP · 2020-09-02 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA211501%22&limit=1) (`fda-drugs-anda211501-2020-09-02-b0b6bb168ed0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA211501." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda211501-v1 SHA-256: 03f0220a45389fd204ca9e1b1f95fc9dbd5a46ef55ef8f8116eb6c25c9b66512.

---

<a id="fda-drugs-anda212081-v1"></a>

## Drugs@FDA application ANDA212081

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212081 with status AP dated 2020-12-16, and names icatibant acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212081:v1`
- Evidence domain: Regulatory
- Date in source: 2020-12-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212081/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda212081-v1
- Content SHA-256: `ac97a27f050e84c0fc416bc8985a85a0478eb10ea6521cedb3a6922144cb6ccc`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212081 ([`fda-drugs-anda212081-2020-12-16-46b17964c3c6`](#source-fda-drugs-anda212081-2020-12-16-46b17964c3c6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212081 with status AP dated 2020-12-16, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda212081-2020-12-16-46b17964c3c6`](#source-fda-drugs-anda212081-2020-12-16-46b17964c3c6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212081 with status AP dated 2020-12-16, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda212081-2020-12-16-46b17964c3c6`](#source-fda-drugs-anda212081-2020-12-16-46b17964c3c6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212081-2020-12-16-46b17964c3c6`](#source-fda-drugs-anda212081-2020-12-16-46b17964c3c6))

### Sources

<a id="source-fda-drugs-anda212081-2020-12-16-46b17964c3c6"></a>
- **Drugs@FDA application ANDA212081 · original submission status AP · 2020-12-16 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212081%22&limit=1) (`fda-drugs-anda212081-2020-12-16-46b17964c3c6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212081." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda212081-v1 SHA-256: ac97a27f050e84c0fc416bc8985a85a0478eb10ea6521cedb3a6922144cb6ccc.

---

<a id="fda-drugs-anda212446-v1"></a>

## Drugs@FDA application ANDA212446

> The official Drugs@FDA dataset lists original submission 1 for ANDA 212446 with status AP dated 2020-07-13, and names icatibant acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda212446:v1`
- Evidence domain: Regulatory
- Date in source: 2020-07-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda212446/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda212446-v1
- Content SHA-256: `728d55e3e6f9edc0d82adf8f50342db2273d8df6b749c0d6de95d70113a8173a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA212446 ([`fda-drugs-anda212446-2020-07-13-60bac129ae52`](#source-fda-drugs-anda212446-2020-07-13-60bac129ae52))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 212446 with status AP dated 2020-07-13, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda212446-2020-07-13-60bac129ae52`](#source-fda-drugs-anda212446-2020-07-13-60bac129ae52))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 212446 with status AP dated 2020-07-13, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda212446-2020-07-13-60bac129ae52`](#source-fda-drugs-anda212446-2020-07-13-60bac129ae52))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda212446-2020-07-13-60bac129ae52`](#source-fda-drugs-anda212446-2020-07-13-60bac129ae52))

### Sources

<a id="source-fda-drugs-anda212446-2020-07-13-60bac129ae52"></a>
- **Drugs@FDA application ANDA212446 · original submission status AP · 2020-07-13 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA212446%22&limit=1) (`fda-drugs-anda212446-2020-07-13-60bac129ae52`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA212446." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda212446-v1 SHA-256: 728d55e3e6f9edc0d82adf8f50342db2273d8df6b749c0d6de95d70113a8173a.

---

<a id="fda-drugs-anda213054-v1"></a>

## Drugs@FDA application ANDA213054

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213054 with status AP dated 2020-10-05, and names icatibant acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213054:v1`
- Evidence domain: Regulatory
- Date in source: 2020-10-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213054/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda213054-v1
- Content SHA-256: `bd3650969613e70388c5b9c15fba3f9f728c07303f6a41a0bbfad584597f5ba0`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213054 ([`fda-drugs-anda213054-2020-10-05-2232dd10f449`](#source-fda-drugs-anda213054-2020-10-05-2232dd10f449))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213054 with status AP dated 2020-10-05, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda213054-2020-10-05-2232dd10f449`](#source-fda-drugs-anda213054-2020-10-05-2232dd10f449))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213054 with status AP dated 2020-10-05, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda213054-2020-10-05-2232dd10f449`](#source-fda-drugs-anda213054-2020-10-05-2232dd10f449))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213054-2020-10-05-2232dd10f449`](#source-fda-drugs-anda213054-2020-10-05-2232dd10f449))

### Sources

<a id="source-fda-drugs-anda213054-2020-10-05-2232dd10f449"></a>
- **Drugs@FDA application ANDA213054 · original submission status AP · 2020-10-05 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213054%22&limit=1) (`fda-drugs-anda213054-2020-10-05-2232dd10f449`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213054." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda213054-v1 SHA-256: bd3650969613e70388c5b9c15fba3f9f728c07303f6a41a0bbfad584597f5ba0.

---

<a id="fda-drugs-anda213222-v1"></a>

## Drugs@FDA application ANDA213222

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213222 with status AP dated 2021-05-21, and names icatibant acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213222:v1`
- Evidence domain: Regulatory
- Date in source: 2021-05-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213222/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda213222-v1
- Content SHA-256: `4a2812713dab3ad2a67a039dbb06a262a9fbe1a73cac0b5239482985928a5906`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213222 ([`fda-drugs-anda213222-2021-05-21-294f80b1003a`](#source-fda-drugs-anda213222-2021-05-21-294f80b1003a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213222 with status AP dated 2021-05-21, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda213222-2021-05-21-294f80b1003a`](#source-fda-drugs-anda213222-2021-05-21-294f80b1003a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213222 with status AP dated 2021-05-21, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda213222-2021-05-21-294f80b1003a`](#source-fda-drugs-anda213222-2021-05-21-294f80b1003a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213222-2021-05-21-294f80b1003a`](#source-fda-drugs-anda213222-2021-05-21-294f80b1003a))

### Sources

<a id="source-fda-drugs-anda213222-2021-05-21-294f80b1003a"></a>
- **Drugs@FDA application ANDA213222 · original submission status AP · 2021-05-21 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213222%22&limit=1) (`fda-drugs-anda213222-2021-05-21-294f80b1003a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213222." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda213222-v1 SHA-256: 4a2812713dab3ad2a67a039dbb06a262a9fbe1a73cac0b5239482985928a5906.

---

<a id="fda-drugs-anda213521-v1"></a>

## Drugs@FDA application ANDA213521

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213521 with status AP dated 2023-08-14, and names icatibant acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213521:v1`
- Evidence domain: Regulatory
- Date in source: 2023-08-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213521/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda213521-v1
- Content SHA-256: `eb9061ebe29943012a2cf8e560064015678c0b4309ac87523fb9cbb2a902b1d0`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213521 ([`fda-drugs-anda213521-2023-08-14-aa0d5fd1f908`](#source-fda-drugs-anda213521-2023-08-14-aa0d5fd1f908))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213521 with status AP dated 2023-08-14, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda213521-2023-08-14-aa0d5fd1f908`](#source-fda-drugs-anda213521-2023-08-14-aa0d5fd1f908))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213521 with status AP dated 2023-08-14, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda213521-2023-08-14-aa0d5fd1f908`](#source-fda-drugs-anda213521-2023-08-14-aa0d5fd1f908))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213521-2023-08-14-aa0d5fd1f908`](#source-fda-drugs-anda213521-2023-08-14-aa0d5fd1f908))

### Sources

<a id="source-fda-drugs-anda213521-2023-08-14-aa0d5fd1f908"></a>
- **Drugs@FDA application ANDA213521 · original submission status AP · 2023-08-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213521%22&limit=1) (`fda-drugs-anda213521-2023-08-14-aa0d5fd1f908`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213521." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda213521-v1 SHA-256: eb9061ebe29943012a2cf8e560064015678c0b4309ac87523fb9cbb2a902b1d0.

---

<a id="fda-drugs-anda213773-v1"></a>

## Drugs@FDA application ANDA213773

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213773 with status AP dated 2024-06-14, and names icatibant acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213773:v1`
- Evidence domain: Regulatory
- Date in source: 2024-06-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213773/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda213773-v1
- Content SHA-256: `27d05646943f003ca03c13ed4692ce820d35f9a03e6ee13a534aae92c020fb0f`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213773 ([`fda-drugs-anda213773-2024-06-14-07be43c44332`](#source-fda-drugs-anda213773-2024-06-14-07be43c44332))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213773 with status AP dated 2024-06-14, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda213773-2024-06-14-07be43c44332`](#source-fda-drugs-anda213773-2024-06-14-07be43c44332))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213773 with status AP dated 2024-06-14, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-anda213773-2024-06-14-07be43c44332`](#source-fda-drugs-anda213773-2024-06-14-07be43c44332))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213773-2024-06-14-07be43c44332`](#source-fda-drugs-anda213773-2024-06-14-07be43c44332))

### Sources

<a id="source-fda-drugs-anda213773-2024-06-14-07be43c44332"></a>
- **Drugs@FDA application ANDA213773 · original submission status AP · 2024-06-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213773%22&limit=1) (`fda-drugs-anda213773-2024-06-14-07be43c44332`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213773." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-anda213773-v1 SHA-256: 27d05646943f003ca03c13ed4692ce820d35f9a03e6ee13a534aae92c020fb0f.

---

<a id="fda-drugs-nda022150-v1"></a>

## Drugs@FDA application NDA022150

> The official Drugs@FDA dataset lists original submission 1 for NDA 022150 with status AP dated 2011-08-25, and names icatibant acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda022150:v1`
- Evidence domain: Regulatory
- Date in source: 2011-08-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda022150/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-nda022150-v1
- Content SHA-256: `b8e1991583214a4505bb0b89085be91caf1c5d948fe0d0fb84ee03b1ac6b713c`

### Claims and source pins

#### Headline

Drugs@FDA application NDA022150 ([`fda-drugs-nda022150-2011-08-25-5aab86a9f7cc`](#source-fda-drugs-nda022150-2011-08-25-5aab86a9f7cc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 022150 with status AP dated 2011-08-25, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-nda022150-2011-08-25-5aab86a9f7cc`](#source-fda-drugs-nda022150-2011-08-25-5aab86a9f7cc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 022150 with status AP dated 2011-08-25, and names icatibant acetate among the application record's active ingredients. ([`fda-drugs-nda022150-2011-08-25-5aab86a9f7cc`](#source-fda-drugs-nda022150-2011-08-25-5aab86a9f7cc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda022150-2011-08-25-5aab86a9f7cc`](#source-fda-drugs-nda022150-2011-08-25-5aab86a9f7cc))

### Sources

<a id="source-fda-drugs-nda022150-2011-08-25-5aab86a9f7cc"></a>
- **Drugs@FDA application NDA022150 · original submission status AP · 2011-08-25 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA022150%22&limit=1) (`fda-drugs-nda022150-2011-08-25-5aab86a9f7cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA022150." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#fda-drugs-nda022150-v1 SHA-256: b8e1991583214a4505bb0b89085be91caf1c5d948fe0d0fb84ee03b1ac6b713c.

---

<a id="federal-register-2011-12543-v1"></a>

## Federal Register notice 2011-12543

> The Federal Register published notice 2011-12543, attributed to FDA and its parent HHS department, on 2011-05-23. Its official title is “Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.

- Evidence object: `story:federal-register-2011-12543:v1`
- Evidence domain: Regulatory
- Date in source: 2011-05-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2011-12543/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#federal-register-2011-12543-v1
- Content SHA-256: `bdfa605120b602029299415cfefd4eb56adb831b91a887f5e560e0e9941f2b27`

### Claims and source pins

#### Headline

Federal Register notice 2011-12543 ([`federal-register-2011-12543-d4ef2defef02`](#source-federal-register-2011-12543-d4ef2defef02))

#### Summary

The Federal Register published notice 2011-12543, attributed to FDA and its parent HHS department, on 2011-05-23. Its official title is “Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant. ([`federal-register-2011-12543-d4ef2defef02`](#source-federal-register-2011-12543-d4ef2defef02))

#### Paragraph 1

The Federal Register published notice 2011-12543, attributed to FDA and its parent HHS department, on 2011-05-23. Its official title is “Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant. ([`federal-register-2011-12543-d4ef2defef02`](#source-federal-register-2011-12543-d4ef2defef02))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2011-12543-d4ef2defef02`](#source-federal-register-2011-12543-d4ef2defef02))

### Sources

<a id="source-federal-register-2011-12543-d4ef2defef02"></a>
- **Federal Register notice 2011-12543 · published 2011-05-23 · Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2011-05-23/pdf/2011-12543.pdf) (`federal-register-2011-12543-d4ef2defef02`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2011-12543." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#federal-register-2011-12543-v1 SHA-256: bdfa605120b602029299415cfefd4eb56adb831b91a887f5e560e0e9941f2b27.

---

<a id="federal-register-2014-07331-v1"></a>

## Federal Register notice 2014-07331

> The Federal Register published notice 2014-07331, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FIRAZYR,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.

- Evidence object: `story:federal-register-2014-07331:v1`
- Evidence domain: Regulatory
- Date in source: 2014-04-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2014-07331/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#federal-register-2014-07331-v1
- Content SHA-256: `df22577ea01d18a804f211ae8d34e80a3afcfed2eae62fa1cf92da3053c4f9b5`

### Claims and source pins

#### Headline

Federal Register notice 2014-07331 ([`federal-register-2014-07331-8f016eac776a`](#source-federal-register-2014-07331-8f016eac776a))

#### Summary

The Federal Register published notice 2014-07331, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FIRAZYR,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant. ([`federal-register-2014-07331-8f016eac776a`](#source-federal-register-2014-07331-8f016eac776a))

#### Paragraph 1

The Federal Register published notice 2014-07331, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FIRAZYR,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant. ([`federal-register-2014-07331-8f016eac776a`](#source-federal-register-2014-07331-8f016eac776a))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2014-07331-8f016eac776a`](#source-federal-register-2014-07331-8f016eac776a))

### Sources

<a id="source-federal-register-2014-07331-8f016eac776a"></a>
- **Federal Register notice 2014-07331 · published 2014-04-02 · Determination of Regulatory Review Period for Purposes of Patent Extension; FIRAZYR** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07331.pdf) (`federal-register-2014-07331-8f016eac776a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2014-07331." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#federal-register-2014-07331-v1 SHA-256: df22577ea01d18a804f211ae8d34e80a3afcfed2eae62fa1cf92da3053c4f9b5.

---

<a id="federal-register-2023-04175-v1"></a>

## Federal Register notice 2023-04175

> The Federal Register published notice 2023-04175, attributed to FDA and its parent HHS department, on 2023-03-01. Its official title is “Mylan Pharmaceuticals Inc., et.al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.

- Evidence object: `story:federal-register-2023-04175:v1`
- Evidence domain: Regulatory
- Date in source: 2023-03-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-04175/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#federal-register-2023-04175-v1
- Content SHA-256: `22cde7f45a6df00f293b9072551078c9c9a6a7f05a2c16f19c3bd10b0ddb6b09`

### Claims and source pins

#### Headline

Federal Register notice 2023-04175 ([`federal-register-2023-04175-cc91db93353b`](#source-federal-register-2023-04175-cc91db93353b))

#### Summary

The Federal Register published notice 2023-04175, attributed to FDA and its parent HHS department, on 2023-03-01. Its official title is “Mylan Pharmaceuticals Inc., et.al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant. ([`federal-register-2023-04175-cc91db93353b`](#source-federal-register-2023-04175-cc91db93353b))

#### Paragraph 1

The Federal Register published notice 2023-04175, attributed to FDA and its parent HHS department, on 2023-03-01. Its official title is “Mylan Pharmaceuticals Inc., et.al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant. ([`federal-register-2023-04175-cc91db93353b`](#source-federal-register-2023-04175-cc91db93353b))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-04175-cc91db93353b`](#source-federal-register-2023-04175-cc91db93353b))

### Sources

<a id="source-federal-register-2023-04175-cc91db93353b"></a>
- **Federal Register notice 2023-04175 · published 2023-03-01 · Mylan Pharmaceuticals Inc., et.al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-03-01/pdf/2023-04175.pdf) (`federal-register-2023-04175-cc91db93353b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-04175." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#federal-register-2023-04175-v1 SHA-256: 22cde7f45a6df00f293b9072551078c9c9a6a7f05a2c16f19c3bd10b0ddb6b09.

---

<a id="federal-register-e7-24812-v1"></a>

## Federal Register notice E7-24812

> The Federal Register published notice E7-24812, attributed to FDA and its parent HHS department, on 2007-12-21. Its official title is “Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.

- Evidence object: `story:federal-register-e7-24812:v1`
- Evidence domain: Regulatory
- Date in source: 2007-12-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-e7-24812/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#federal-register-e7-24812-v1
- Content SHA-256: `87f96237954434d1cd61134bc3c9fb722e0bb751795dc3c0e5fda1470efd6aa6`

### Claims and source pins

#### Headline

Federal Register notice E7-24812 ([`federal-register-e7-24812-bdbf6f1885e7`](#source-federal-register-e7-24812-bdbf6f1885e7))

#### Summary

The Federal Register published notice E7-24812, attributed to FDA and its parent HHS department, on 2007-12-21. Its official title is “Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant. ([`federal-register-e7-24812-bdbf6f1885e7`](#source-federal-register-e7-24812-bdbf6f1885e7))

#### Paragraph 1

The Federal Register published notice E7-24812, attributed to FDA and its parent HHS department, on 2007-12-21. Its official title is “Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant. ([`federal-register-e7-24812-bdbf6f1885e7`](#source-federal-register-e7-24812-bdbf6f1885e7))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e7-24812-bdbf6f1885e7`](#source-federal-register-e7-24812-bdbf6f1885e7))

### Sources

<a id="source-federal-register-e7-24812-bdbf6f1885e7"></a>
- **Federal Register notice E7-24812 · published 2007-12-21 · Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2007-12-21/pdf/E7-24812.pdf) (`federal-register-e7-24812-bdbf6f1885e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E7-24812." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#federal-register-e7-24812-v1 SHA-256: 87f96237954434d1cd61134bc3c9fb722e0bb751795dc3c0e5fda1470efd6aa6.

---

<a id="pubmed-pmid-15563238-icatibant-v1"></a>

## Icatibant: HOE 140, JE 049, JE049.

> PubMed lists PMID 15563238 in Drugs in R&D as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15563238-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-10-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15563238-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-15563238-icatibant-v1
- Content SHA-256: `d6615d679531c7a6a54b42fc8c35e35ff25b193e0ff0d83b07899faee49d50ae`

### Claims and source pins

#### Headline

Icatibant: HOE 140, JE 049, JE049. ([`pubmed-observation-pmid-15563238-2018-10-25-59b2d39c5a90`](#source-pubmed-observation-pmid-15563238-2018-10-25-59b2d39c5a90))

#### Summary

PubMed lists PMID 15563238 in Drugs in R&D as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15563238-2018-10-25-59b2d39c5a90`](#source-pubmed-observation-pmid-15563238-2018-10-25-59b2d39c5a90))

#### Paragraph 1

PubMed lists PMID 15563238 in Drugs in R&D as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15563238-2018-10-25-59b2d39c5a90`](#source-pubmed-observation-pmid-15563238-2018-10-25-59b2d39c5a90))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15563238-2018-10-25-59b2d39c5a90`](#source-pubmed-observation-pmid-15563238-2018-10-25-59b2d39c5a90))

### Sources

<a id="source-pubmed-observation-pmid-15563238-2018-10-25-59b2d39c5a90"></a>
- **Icatibant: HOE 140, JE 049, JE049. · retained source version 1:2018-10-25:current:59b2d39c5a902fdf9f2cce64ee38e4fc0d644098c6a59e8ec4bed122b4b066f9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15563238/) (`pubmed-observation-pmid-15563238-2018-10-25-59b2d39c5a90`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant: HOE 140, JE 049, JE049." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-15563238-icatibant-v1 SHA-256: d6615d679531c7a6a54b42fc8c35e35ff25b193e0ff0d83b07899faee49d50ae.

---

<a id="pubmed-pmid-15991885-icatibant-v1"></a>

## Icatibant: HOE 140, JE 049, JE049.

> PubMed lists PMID 15991885 in Drugs in R&D as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15991885-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-10-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15991885-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-15991885-icatibant-v1
- Content SHA-256: `8cfea13093502e91ddb322aac08944d4bee14031217ddd5d61a59852e53c5961`

### Claims and source pins

#### Headline

Icatibant: HOE 140, JE 049, JE049. ([`pubmed-observation-pmid-15991885-2018-10-25-5ae456c1c682`](#source-pubmed-observation-pmid-15991885-2018-10-25-5ae456c1c682))

#### Summary

PubMed lists PMID 15991885 in Drugs in R&D as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15991885-2018-10-25-5ae456c1c682`](#source-pubmed-observation-pmid-15991885-2018-10-25-5ae456c1c682))

#### Paragraph 1

PubMed lists PMID 15991885 in Drugs in R&D as Journal Article, Review, with publication-date metadata of 2005 (year precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15991885-2018-10-25-5ae456c1c682`](#source-pubmed-observation-pmid-15991885-2018-10-25-5ae456c1c682))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15991885-2018-10-25-5ae456c1c682`](#source-pubmed-observation-pmid-15991885-2018-10-25-5ae456c1c682))

### Sources

<a id="source-pubmed-observation-pmid-15991885-2018-10-25-5ae456c1c682"></a>
- **Icatibant: HOE 140, JE 049, JE049. · retained source version 1:2018-10-25:current:5ae456c1c682d0773e7d865add704e2fd4de5693b18c6ff65c83f482d79e40e9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15991885/) (`pubmed-observation-pmid-15991885-2018-10-25-5ae456c1c682`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant: HOE 140, JE 049, JE049." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-15991885-icatibant-v1 SHA-256: 8cfea13093502e91ddb322aac08944d4bee14031217ddd5d61a59852e53c5961.

---

<a id="pubmed-pmid-17418383-icatibant-v1"></a>

## Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).

> PubMed lists PMID 17418383 in The Journal of allergy and clinical immunology as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2007-04-05 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17418383-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2014-11-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17418383-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-17418383-icatibant-v1
- Content SHA-256: `40bd449bd129d05fa50c101651da65a727c5c864cb53675fae451c61d3dc2975`

### Claims and source pins

#### Headline

Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). ([`pubmed-observation-pmid-17418383-2014-11-20-fc386cafb808`](#source-pubmed-observation-pmid-17418383-2014-11-20-fc386cafb808))

#### Summary

PubMed lists PMID 17418383 in The Journal of allergy and clinical immunology as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2007-04-05 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17418383-2014-11-20-fc386cafb808`](#source-pubmed-observation-pmid-17418383-2014-11-20-fc386cafb808))

#### Paragraph 1

PubMed lists PMID 17418383 in The Journal of allergy and clinical immunology as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2007-04-05 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17418383-2014-11-20-fc386cafb808`](#source-pubmed-observation-pmid-17418383-2014-11-20-fc386cafb808))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17418383-2014-11-20-fc386cafb808`](#source-pubmed-observation-pmid-17418383-2014-11-20-fc386cafb808))

### Sources

<a id="source-pubmed-observation-pmid-17418383-2014-11-20-fc386cafb808"></a>
- **Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). · retained source version 1:2014-11-20:current:fc386cafb80811bdcf618f6eed407774fac4e11db8a131864851154f454e3b35** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17418383/) (`pubmed-observation-pmid-17418383-2014-11-20-fc386cafb808`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant)." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-17418383-icatibant-v1 SHA-256: 40bd449bd129d05fa50c101651da65a727c5c864cb53675fae451c61d3dc2975.

---

<a id="pubmed-pmid-20135020-icatibant-v1"></a>

## Icatibant for hereditary angioedema.

> PubMed lists PMID 20135020 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2009-12 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20135020-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-10-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20135020-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-20135020-icatibant-v1
- Content SHA-256: `4ee07d23e72e876d9f0c77f32aa4a615a1cddec8e6ac13a017cda4dbf42af839`

### Claims and source pins

#### Headline

Icatibant for hereditary angioedema. ([`pubmed-observation-pmid-20135020-2025-10-22-185eb56af1c1`](#source-pubmed-observation-pmid-20135020-2025-10-22-185eb56af1c1))

#### Summary

PubMed lists PMID 20135020 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2009-12 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20135020-2025-10-22-185eb56af1c1`](#source-pubmed-observation-pmid-20135020-2025-10-22-185eb56af1c1))

#### Paragraph 1

PubMed lists PMID 20135020 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2009-12 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20135020-2025-10-22-185eb56af1c1`](#source-pubmed-observation-pmid-20135020-2025-10-22-185eb56af1c1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20135020-2025-10-22-185eb56af1c1`](#source-pubmed-observation-pmid-20135020-2025-10-22-185eb56af1c1))

### Sources

<a id="source-pubmed-observation-pmid-20135020-2025-10-22-185eb56af1c1"></a>
- **Icatibant for hereditary angioedema. · retained source version 1:2025-10-22:current:185eb56af1c1799fe5d4c1e23b109c1727a6f20e8536d2d53c89a32e97ccbd45** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20135020/) (`pubmed-observation-pmid-20135020-2025-10-22-185eb56af1c1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant for hereditary angioedema." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-20135020-icatibant-v1 SHA-256: 4ee07d23e72e876d9f0c77f32aa4a615a1cddec8e6ac13a017cda4dbf42af839.

---

<a id="pubmed-pmid-21595592-icatibant-v1"></a>

## Icatibant in hereditary angioedema: news and challenges.

> PubMed lists PMID 21595592 in Expert review of clinical immunology as Journal Article, Review, with publication-date metadata of 2011-05 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-21595592-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21595592-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-21595592-icatibant-v1
- Content SHA-256: `fb8282b2c8cb71a979a1880f4062609bd81f1b3aa38c6a8493a7365ee3ab1a9d`

### Claims and source pins

#### Headline

Icatibant in hereditary angioedema: news and challenges. ([`pubmed-observation-pmid-21595592-2013-11-21-cb905e81ebe1`](#source-pubmed-observation-pmid-21595592-2013-11-21-cb905e81ebe1))

#### Summary

PubMed lists PMID 21595592 in Expert review of clinical immunology as Journal Article, Review, with publication-date metadata of 2011-05 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21595592-2013-11-21-cb905e81ebe1`](#source-pubmed-observation-pmid-21595592-2013-11-21-cb905e81ebe1))

#### Paragraph 1

PubMed lists PMID 21595592 in Expert review of clinical immunology as Journal Article, Review, with publication-date metadata of 2011-05 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21595592-2013-11-21-cb905e81ebe1`](#source-pubmed-observation-pmid-21595592-2013-11-21-cb905e81ebe1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21595592-2013-11-21-cb905e81ebe1`](#source-pubmed-observation-pmid-21595592-2013-11-21-cb905e81ebe1))

### Sources

<a id="source-pubmed-observation-pmid-21595592-2013-11-21-cb905e81ebe1"></a>
- **Icatibant in hereditary angioedema: news and challenges. · retained source version 1:2013-11-21:current:cb905e81ebe125e87d2f0f3ddc04cb9414d5a0224ba3d2d40e73c50b054d3ea1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21595592/) (`pubmed-observation-pmid-21595592-2013-11-21-cb905e81ebe1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant in hereditary angioedema: news and challenges." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-21595592-icatibant-v1 SHA-256: fb8282b2c8cb71a979a1880f4062609bd81f1b3aa38c6a8493a7365ee3ab1a9d.

---

<a id="pubmed-pmid-21788245-icatibant-v1"></a>

## Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Management of adult patients with icatibant in hereditary angioedema.

> PubMed lists PMID 21788245 in Emergency medicine journal : EMJ as Journal Article, Review, with publication-date metadata of 2011-08 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-21788245-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21788245-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-21788245-icatibant-v1
- Content SHA-256: `0dad858f37f596090c18d2cb9a8073a2cbfff8d576029de00c77aa765819d68c`

### Claims and source pins

#### Headline

Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Management of adult patients with icatibant in hereditary angioedema. ([`pubmed-observation-pmid-21788245-2013-11-21-d04871fd14b3`](#source-pubmed-observation-pmid-21788245-2013-11-21-d04871fd14b3))

#### Summary

PubMed lists PMID 21788245 in Emergency medicine journal : EMJ as Journal Article, Review, with publication-date metadata of 2011-08 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21788245-2013-11-21-d04871fd14b3`](#source-pubmed-observation-pmid-21788245-2013-11-21-d04871fd14b3))

#### Paragraph 1

PubMed lists PMID 21788245 in Emergency medicine journal : EMJ as Journal Article, Review, with publication-date metadata of 2011-08 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21788245-2013-11-21-d04871fd14b3`](#source-pubmed-observation-pmid-21788245-2013-11-21-d04871fd14b3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21788245-2013-11-21-d04871fd14b3`](#source-pubmed-observation-pmid-21788245-2013-11-21-d04871fd14b3))

### Sources

<a id="source-pubmed-observation-pmid-21788245-2013-11-21-d04871fd14b3"></a>
- **Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Management of adult patients with icatibant in hereditary angioedema. · retained source version 1:2013-11-21:current:d04871fd14b3780d2403642af30daae066ee35351a416d9564c84c58df7fef69** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21788245/) (`pubmed-observation-pmid-21788245-2013-11-21-d04871fd14b3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Management of adult patients with icatibant in hereditary angioedema." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-21788245-icatibant-v1 SHA-256: 0dad858f37f596090c18d2cb9a8073a2cbfff8d576029de00c77aa765819d68c.

---

<a id="pubmed-pmid-22970904-icatibant-v1"></a>

## Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems.

> PubMed lists PMID 22970904 in Expert opinion on pharmacotherapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-09-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22970904-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22970904-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-22970904-icatibant-v1
- Content SHA-256: `0ff75f75c6e963646ad095696de9327eca447a6fe3eedbe7f6c52bf2dfd4c813`

### Claims and source pins

#### Headline

Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. ([`pubmed-observation-pmid-22970904-2022-03-30-8def6900d240`](#source-pubmed-observation-pmid-22970904-2022-03-30-8def6900d240))

#### Summary

PubMed lists PMID 22970904 in Expert opinion on pharmacotherapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-09-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22970904-2022-03-30-8def6900d240`](#source-pubmed-observation-pmid-22970904-2022-03-30-8def6900d240))

#### Paragraph 1

PubMed lists PMID 22970904 in Expert opinion on pharmacotherapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-09-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22970904-2022-03-30-8def6900d240`](#source-pubmed-observation-pmid-22970904-2022-03-30-8def6900d240))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22970904-2022-03-30-8def6900d240`](#source-pubmed-observation-pmid-22970904-2022-03-30-8def6900d240))

### Sources

<a id="source-pubmed-observation-pmid-22970904-2022-03-30-8def6900d240"></a>
- **Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. · retained source version 1:2022-03-30:current:8def6900d240a2dbaf4d515cb72bf7082bf7143888152f7d5069bae4d2b947f8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22970904/) (`pubmed-observation-pmid-22970904-2022-03-30-8def6900d240`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-22970904-icatibant-v1 SHA-256: 0ff75f75c6e963646ad095696de9327eca447a6fe3eedbe7f6c52bf2dfd4c813.

---

<a id="pubmed-pmid-23249729-icatibant-v1"></a>

## Icatibant for the treatment of hereditary angioedema.

> PubMed lists PMID 23249729 in The Annals of pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2012-12-18 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23249729-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23249729-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-23249729-icatibant-v1
- Content SHA-256: `33411f8384ceedb0fe97b624b2004e5224e59c8dd44c6448620da300ed5b7269`

### Claims and source pins

#### Headline

Icatibant for the treatment of hereditary angioedema. ([`pubmed-observation-pmid-23249729-2017-11-16-40bc755b4ca5`](#source-pubmed-observation-pmid-23249729-2017-11-16-40bc755b4ca5))

#### Summary

PubMed lists PMID 23249729 in The Annals of pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2012-12-18 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23249729-2017-11-16-40bc755b4ca5`](#source-pubmed-observation-pmid-23249729-2017-11-16-40bc755b4ca5))

#### Paragraph 1

PubMed lists PMID 23249729 in The Annals of pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2012-12-18 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23249729-2017-11-16-40bc755b4ca5`](#source-pubmed-observation-pmid-23249729-2017-11-16-40bc755b4ca5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23249729-2017-11-16-40bc755b4ca5`](#source-pubmed-observation-pmid-23249729-2017-11-16-40bc755b4ca5))

### Sources

<a id="source-pubmed-observation-pmid-23249729-2017-11-16-40bc755b4ca5"></a>
- **Icatibant for the treatment of hereditary angioedema. · retained source version 1:2017-11-16:current:40bc755b4ca5b4e5589023f1ebb3f7dbe3a3ef20c47ba1428afe49c5b9ca73ef** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23249729/) (`pubmed-observation-pmid-23249729-2017-11-16-40bc755b4ca5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant for the treatment of hereditary angioedema." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-23249729-icatibant-v1 SHA-256: 33411f8384ceedb0fe97b624b2004e5224e59c8dd44c6448620da300ed5b7269.

---

<a id="pubmed-pmid-24749847-icatibant-v1"></a>

## Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.

> PubMed lists PMID 24749847 in Clinical and experimental immunology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2014-08 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24749847-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24749847-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-24749847-icatibant-v1
- Content SHA-256: `32513039caf311c8a231a0f0fc8f8efcaec3ce5915667db29f9a46e9613a4df8`

### Claims and source pins

#### Headline

Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. ([`pubmed-observation-pmid-24749847-2026-11-08-855d8c189e59`](#source-pubmed-observation-pmid-24749847-2026-11-08-855d8c189e59))

#### Summary

PubMed lists PMID 24749847 in Clinical and experimental immunology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2014-08 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24749847-2026-11-08-855d8c189e59`](#source-pubmed-observation-pmid-24749847-2026-11-08-855d8c189e59))

#### Paragraph 1

PubMed lists PMID 24749847 in Clinical and experimental immunology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2014-08 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24749847-2026-11-08-855d8c189e59`](#source-pubmed-observation-pmid-24749847-2026-11-08-855d8c189e59))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24749847-2026-11-08-855d8c189e59`](#source-pubmed-observation-pmid-24749847-2026-11-08-855d8c189e59))

### Sources

<a id="source-pubmed-observation-pmid-24749847-2026-11-08-855d8c189e59"></a>
- **Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. · retained source version 1:2026-11-08:current:855d8c189e597b76dc46c231025633a128346fd31bdd51ac459d0e0512632ee4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24749847/) (`pubmed-observation-pmid-24749847-2026-11-08-855d8c189e59`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-24749847-icatibant-v1 SHA-256: 32513039caf311c8a231a0f0fc8f8efcaec3ce5915667db29f9a46e9613a4df8.

---

<a id="pubmed-pmid-24931134-icatibant-v1"></a>

## \[Prophylactic use of icatibant before tracheal intubation of a patient with hereditary angioedema type III. (A literature review of perioperative management of patients with hereditary angioedema typ…

> PubMed lists PMID 24931134 in Revista espanola de anestesiologia y reanimacion as Case Reports, Journal Article, Review, with publication-date metadata of 2014-06-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24931134-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-12-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24931134-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-24931134-icatibant-v1
- Content SHA-256: `4beb4478e209ca4f492f1e6aeaf07952dd92f3e8912e345d2411d97f59adf419`

### Claims and source pins

#### Headline

\[Prophylactic use of icatibant before tracheal intubation of a patient with hereditary angioedema type III. (A literature review of perioperative management of patients with hereditary angioedema typ… ([`pubmed-observation-pmid-24931134-2016-12-30-928eb71ec5e7`](#source-pubmed-observation-pmid-24931134-2016-12-30-928eb71ec5e7))

#### Summary

PubMed lists PMID 24931134 in Revista espanola de anestesiologia y reanimacion as Case Reports, Journal Article, Review, with publication-date metadata of 2014-06-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24931134-2016-12-30-928eb71ec5e7`](#source-pubmed-observation-pmid-24931134-2016-12-30-928eb71ec5e7))

#### Paragraph 1

PubMed lists PMID 24931134 in Revista espanola de anestesiologia y reanimacion as Case Reports, Journal Article, Review, with publication-date metadata of 2014-06-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24931134-2016-12-30-928eb71ec5e7`](#source-pubmed-observation-pmid-24931134-2016-12-30-928eb71ec5e7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24931134-2016-12-30-928eb71ec5e7`](#source-pubmed-observation-pmid-24931134-2016-12-30-928eb71ec5e7))

### Sources

<a id="source-pubmed-observation-pmid-24931134-2016-12-30-928eb71ec5e7"></a>
- **\[Prophylactic use of icatibant before tracheal intubation of a patient with hereditary angioedema type III. (A literature review of perioperative management of patients with hereditary angioedema type III)\]. · retained source version 1:2016-12-30:current:928eb71ec5e76875a3cbcac1c42a6fe487eedc2571f0f61ef35c8a7895ee4f40** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24931134/) (`pubmed-observation-pmid-24931134-2016-12-30-928eb71ec5e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Prophylactic use of icatibant before tracheal intubation of a patient with hereditary angioedema type III. (A literature review of perioperative management of patients with hereditary angioedema typ…." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-24931134-icatibant-v1 SHA-256: 4beb4478e209ca4f492f1e6aeaf07952dd92f3e8912e345d2411d97f59adf419.

---

<a id="pubmed-pmid-27123689-icatibant-v1"></a>

## Icatibant as acute treatment for hereditary angioedema in adults.

> PubMed lists PMID 27123689 in Expert review of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2016-05-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27123689-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-03-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27123689-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-27123689-icatibant-v1
- Content SHA-256: `3ec6bae904deccc4589525ce0cd12c6f0d2667ae255f4059f329ab6a53d8dc84`

### Claims and source pins

#### Headline

Icatibant as acute treatment for hereditary angioedema in adults. ([`pubmed-observation-pmid-27123689-2017-03-10-bef89c880563`](#source-pubmed-observation-pmid-27123689-2017-03-10-bef89c880563))

#### Summary

PubMed lists PMID 27123689 in Expert review of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2016-05-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27123689-2017-03-10-bef89c880563`](#source-pubmed-observation-pmid-27123689-2017-03-10-bef89c880563))

#### Paragraph 1

PubMed lists PMID 27123689 in Expert review of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2016-05-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27123689-2017-03-10-bef89c880563`](#source-pubmed-observation-pmid-27123689-2017-03-10-bef89c880563))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27123689-2017-03-10-bef89c880563`](#source-pubmed-observation-pmid-27123689-2017-03-10-bef89c880563))

### Sources

<a id="source-pubmed-observation-pmid-27123689-2017-03-10-bef89c880563"></a>
- **Icatibant as acute treatment for hereditary angioedema in adults. · retained source version 1:2017-03-10:current:bef89c88056344b571518fd380cb8a740578b625263fa08106cdd1be1c904caa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27123689/) (`pubmed-observation-pmid-27123689-2017-03-10-bef89c880563`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant as acute treatment for hereditary angioedema in adults." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-27123689-icatibant-v1 SHA-256: 3ec6bae904deccc4589525ce0cd12c6f0d2667ae255f4059f329ab6a53d8dc84.

---

<a id="pubmed-pmid-30651343-icatibant-v1"></a>

## Angiogenic Host Defense Peptide AG-30/5C and Bradykinin B2 Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells.

> PubMed lists PMID 30651343 in Journal of immunology (Baltimore, Md. : 1950) as Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2019-01-16 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30651343-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-03-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30651343-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-30651343-icatibant-v1
- Content SHA-256: `c284bef45e6990fe86015d60bff4c9a7b61f54f13627626678906426bb0da638`

### Claims and source pins

#### Headline

Angiogenic Host Defense Peptide AG-30/5C and Bradykinin B2 Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells. ([`pubmed-observation-pmid-30651343-2020-03-09-35ff5e2bd39e`](#source-pubmed-observation-pmid-30651343-2020-03-09-35ff5e2bd39e))

#### Summary

PubMed lists PMID 30651343 in Journal of immunology (Baltimore, Md. : 1950) as Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2019-01-16 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30651343-2020-03-09-35ff5e2bd39e`](#source-pubmed-observation-pmid-30651343-2020-03-09-35ff5e2bd39e))

#### Paragraph 1

PubMed lists PMID 30651343 in Journal of immunology (Baltimore, Md. : 1950) as Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2019-01-16 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30651343-2020-03-09-35ff5e2bd39e`](#source-pubmed-observation-pmid-30651343-2020-03-09-35ff5e2bd39e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30651343-2020-03-09-35ff5e2bd39e`](#source-pubmed-observation-pmid-30651343-2020-03-09-35ff5e2bd39e))

### Sources

<a id="source-pubmed-observation-pmid-30651343-2020-03-09-35ff5e2bd39e"></a>
- **Angiogenic Host Defense Peptide AG-30/5C and Bradykinin B2 Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells. · retained source version 1:2020-03-09:current:35ff5e2bd39efe4e242f0d2ab767fc21b605a1d6de5687e42d66b322f9c0782d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30651343/) (`pubmed-observation-pmid-30651343-2020-03-09-35ff5e2bd39e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Angiogenic Host Defense Peptide AG-30/5C and Bradykinin B2 Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-30651343-icatibant-v1 SHA-256: c284bef45e6990fe86015d60bff4c9a7b61f54f13627626678906426bb0da638.

---

<a id="pubmed-pmid-30849486-icatibant-v1"></a>

## The identification and chromatographic separation of a new highly analogous impurity of the active pharmaceutical ingredient icatibant.

> PubMed lists PMID 30849486 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, with publication-date metadata of 2019-03-06 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30849486-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30849486-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-30849486-icatibant-v1
- Content SHA-256: `90ab11d9e66c6095b32e63e6fe3451070197977969e4b0edec31ed91ea0e5600`

### Claims and source pins

#### Headline

The identification and chromatographic separation of a new highly analogous impurity of the active pharmaceutical ingredient icatibant. ([`pubmed-observation-pmid-30849486-2019-07-23-de7faaa3674a`](#source-pubmed-observation-pmid-30849486-2019-07-23-de7faaa3674a))

#### Summary

PubMed lists PMID 30849486 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, with publication-date metadata of 2019-03-06 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30849486-2019-07-23-de7faaa3674a`](#source-pubmed-observation-pmid-30849486-2019-07-23-de7faaa3674a))

#### Paragraph 1

PubMed lists PMID 30849486 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, with publication-date metadata of 2019-03-06 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30849486-2019-07-23-de7faaa3674a`](#source-pubmed-observation-pmid-30849486-2019-07-23-de7faaa3674a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30849486-2019-07-23-de7faaa3674a`](#source-pubmed-observation-pmid-30849486-2019-07-23-de7faaa3674a))

### Sources

<a id="source-pubmed-observation-pmid-30849486-2019-07-23-de7faaa3674a"></a>
- **The identification and chromatographic separation of a new highly analogous impurity of the active pharmaceutical ingredient icatibant. · retained source version 1:2019-07-23:current:de7faaa3674ac9361b01164921ed8860cf13274fa20a73d24540786dd9b310a9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30849486/) (`pubmed-observation-pmid-30849486-2019-07-23-de7faaa3674a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The identification and chromatographic separation of a new highly analogous impurity of the active pharmaceutical ingredient icatibant." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-30849486-icatibant-v1 SHA-256: 90ab11d9e66c6095b32e63e6fe3451070197977969e4b0edec31ed91ea0e5600.

---

<a id="pubmed-pmid-32107042-icatibant-v1"></a>

## Angioedema by MDMA mediated by bradykinin. Role of icatibant acetate.

> PubMed lists PMID 32107042 in Medicina clinica as Letter, with publication-date metadata of 2020-02-24 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32107042-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-05-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32107042-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-32107042-icatibant-v1
- Content SHA-256: `956ed64ecb42ce58b0309b796cad3de69fe28b65707f49e6f10e6f70d4bfb8ea`

### Claims and source pins

#### Headline

Angioedema by MDMA mediated by bradykinin. Role of icatibant acetate. ([`pubmed-observation-pmid-32107042-2021-05-14-831803c2705c`](#source-pubmed-observation-pmid-32107042-2021-05-14-831803c2705c))

#### Summary

PubMed lists PMID 32107042 in Medicina clinica as Letter, with publication-date metadata of 2020-02-24 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32107042-2021-05-14-831803c2705c`](#source-pubmed-observation-pmid-32107042-2021-05-14-831803c2705c))

#### Paragraph 1

PubMed lists PMID 32107042 in Medicina clinica as Letter, with publication-date metadata of 2020-02-24 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32107042-2021-05-14-831803c2705c`](#source-pubmed-observation-pmid-32107042-2021-05-14-831803c2705c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32107042-2021-05-14-831803c2705c`](#source-pubmed-observation-pmid-32107042-2021-05-14-831803c2705c))

### Sources

<a id="source-pubmed-observation-pmid-32107042-2021-05-14-831803c2705c"></a>
- **Angioedema by MDMA mediated by bradykinin. Role of icatibant acetate. · retained source version 1:2021-05-14:current:831803c2705cf2456ab8a1507eae846a5a8850b4dd3f03cbe26836b638b66a9b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32107042/) (`pubmed-observation-pmid-32107042-2021-05-14-831803c2705c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Angioedema by MDMA mediated by bradykinin. Role of icatibant acetate." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-32107042-icatibant-v1 SHA-256: 956ed64ecb42ce58b0309b796cad3de69fe28b65707f49e6f10e6f70d4bfb8ea.

---

<a id="pubmed-pmid-32919903-icatibant-v1"></a>

## Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.

> PubMed lists PMID 32919903 in Allergology international : official journal of the Japanese Society of Allergology as Journal Article, Review, with publication-date metadata of 2020-09-09 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32919903-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-09-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32919903-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-32919903-icatibant-v1
- Content SHA-256: `80317a26c66f0e77fefb7f59fc2ada1c1c85da279dd683e0fdd563d033e14c81`

### Claims and source pins

#### Headline

Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks. ([`pubmed-observation-pmid-32919903-2021-09-03-a0dba0ed0db2`](#source-pubmed-observation-pmid-32919903-2021-09-03-a0dba0ed0db2))

#### Summary

PubMed lists PMID 32919903 in Allergology international : official journal of the Japanese Society of Allergology as Journal Article, Review, with publication-date metadata of 2020-09-09 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32919903-2021-09-03-a0dba0ed0db2`](#source-pubmed-observation-pmid-32919903-2021-09-03-a0dba0ed0db2))

#### Paragraph 1

PubMed lists PMID 32919903 in Allergology international : official journal of the Japanese Society of Allergology as Journal Article, Review, with publication-date metadata of 2020-09-09 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32919903-2021-09-03-a0dba0ed0db2`](#source-pubmed-observation-pmid-32919903-2021-09-03-a0dba0ed0db2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32919903-2021-09-03-a0dba0ed0db2`](#source-pubmed-observation-pmid-32919903-2021-09-03-a0dba0ed0db2))

### Sources

<a id="source-pubmed-observation-pmid-32919903-2021-09-03-a0dba0ed0db2"></a>
- **Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks. · retained source version 1:2021-09-03:current:a0dba0ed0db29fd9354e52e967edf206b44d5a2115bfbbb81617592f1090c781** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32919903/) (`pubmed-observation-pmid-32919903-2021-09-03-a0dba0ed0db2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-32919903-icatibant-v1 SHA-256: 80317a26c66f0e77fefb7f59fc2ada1c1c85da279dd683e0fdd563d033e14c81.

---

<a id="pubmed-pmid-33275101-icatibant-v1"></a>

## Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report.

> PubMed lists PMID 33275101 in Journal of investigational allergology & clinical immunology as Case Reports, Journal Article, with publication-date metadata of 2020-12-04 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33275101-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-12-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33275101-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-33275101-icatibant-v1
- Content SHA-256: `a5ab35d53f759115e1a279ce2e3ff0c6ba1ac666bcc455e87855cec3118d3286`

### Claims and source pins

#### Headline

Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report. ([`pubmed-observation-pmid-33275101-2022-12-07-04c2448d3d78`](#source-pubmed-observation-pmid-33275101-2022-12-07-04c2448d3d78))

#### Summary

PubMed lists PMID 33275101 in Journal of investigational allergology & clinical immunology as Case Reports, Journal Article, with publication-date metadata of 2020-12-04 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33275101-2022-12-07-04c2448d3d78`](#source-pubmed-observation-pmid-33275101-2022-12-07-04c2448d3d78))

#### Paragraph 1

PubMed lists PMID 33275101 in Journal of investigational allergology & clinical immunology as Case Reports, Journal Article, with publication-date metadata of 2020-12-04 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33275101-2022-12-07-04c2448d3d78`](#source-pubmed-observation-pmid-33275101-2022-12-07-04c2448d3d78))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33275101-2022-12-07-04c2448d3d78`](#source-pubmed-observation-pmid-33275101-2022-12-07-04c2448d3d78))

### Sources

<a id="source-pubmed-observation-pmid-33275101-2022-12-07-04c2448d3d78"></a>
- **Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report. · retained source version 1:2022-12-07:current:04c2448d3d782f2dbad8cb143a438b3eb1c7323c3f2f12251251f07df94a38b0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33275101/) (`pubmed-observation-pmid-33275101-2022-12-07-04c2448d3d78`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-33275101-icatibant-v1 SHA-256: a5ab35d53f759115e1a279ce2e3ff0c6ba1ac666bcc455e87855cec3118d3286.

---

<a id="pubmed-pmid-33292436-icatibant-v1"></a>

## Review of icatibant use in the Winnipeg Regional Health Authority.

> PubMed lists PMID 33292436 in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology as Journal Article, with publication-date metadata of 2020-11-11 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33292436-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33292436-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-33292436-icatibant-v1
- Content SHA-256: `823b43e4788057011bd47854766c1345d473b5542e11c7e70f94954870fa1855`

### Claims and source pins

#### Headline

Review of icatibant use in the Winnipeg Regional Health Authority. ([`pubmed-observation-pmid-33292436-2024-03-30-0ee69679bfc0`](#source-pubmed-observation-pmid-33292436-2024-03-30-0ee69679bfc0))

#### Summary

PubMed lists PMID 33292436 in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology as Journal Article, with publication-date metadata of 2020-11-11 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33292436-2024-03-30-0ee69679bfc0`](#source-pubmed-observation-pmid-33292436-2024-03-30-0ee69679bfc0))

#### Paragraph 1

PubMed lists PMID 33292436 in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology as Journal Article, with publication-date metadata of 2020-11-11 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33292436-2024-03-30-0ee69679bfc0`](#source-pubmed-observation-pmid-33292436-2024-03-30-0ee69679bfc0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33292436-2024-03-30-0ee69679bfc0`](#source-pubmed-observation-pmid-33292436-2024-03-30-0ee69679bfc0))

### Sources

<a id="source-pubmed-observation-pmid-33292436-2024-03-30-0ee69679bfc0"></a>
- **Review of icatibant use in the Winnipeg Regional Health Authority. · retained source version 1:2024-03-30:current:0ee69679bfc0962869b09e7898bf01ca6ad142eb73b039e5956dd3dc3917bcf2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33292436/) (`pubmed-observation-pmid-33292436-2024-03-30-0ee69679bfc0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Review of icatibant use in the Winnipeg Regional Health Authority." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-33292436-icatibant-v1 SHA-256: 823b43e4788057011bd47854766c1345d473b5542e11c7e70f94954870fa1855.

---

<a id="pubmed-pmid-33738947-icatibant-v1"></a>

## Real-world off-label use of icatibant for acute management of non-hereditary angioedema.

> PubMed lists PMID 33738947 in Internal medicine journal as Journal Article, with publication-date metadata of 2021-03 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33738947-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-05-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33738947-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-33738947-icatibant-v1
- Content SHA-256: `6c4efff85acbcf45f0481e9ca0181df420366d59f1aeae62b9099b38da817422`

### Claims and source pins

#### Headline

Real-world off-label use of icatibant for acute management of non-hereditary angioedema. ([`pubmed-observation-pmid-33738947-2021-05-31-2261681d2b3a`](#source-pubmed-observation-pmid-33738947-2021-05-31-2261681d2b3a))

#### Summary

PubMed lists PMID 33738947 in Internal medicine journal as Journal Article, with publication-date metadata of 2021-03 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33738947-2021-05-31-2261681d2b3a`](#source-pubmed-observation-pmid-33738947-2021-05-31-2261681d2b3a))

#### Paragraph 1

PubMed lists PMID 33738947 in Internal medicine journal as Journal Article, with publication-date metadata of 2021-03 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33738947-2021-05-31-2261681d2b3a`](#source-pubmed-observation-pmid-33738947-2021-05-31-2261681d2b3a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33738947-2021-05-31-2261681d2b3a`](#source-pubmed-observation-pmid-33738947-2021-05-31-2261681d2b3a))

### Sources

<a id="source-pubmed-observation-pmid-33738947-2021-05-31-2261681d2b3a"></a>
- **Real-world off-label use of icatibant for acute management of non-hereditary angioedema. · retained source version 1:2021-05-31:current:2261681d2b3a96bd39ee09bb9d0f191a0117f8b33e1075825079001aaa463512** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33738947/) (`pubmed-observation-pmid-33738947-2021-05-31-2261681d2b3a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-world off-label use of icatibant for acute management of non-hereditary angioedema." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-33738947-icatibant-v1 SHA-256: 6c4efff85acbcf45f0481e9ca0181df420366d59f1aeae62b9099b38da817422.

---

<a id="pubmed-pmid-33851451-icatibant-v1"></a>

## Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema.

> PubMed lists PMID 33851451 in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-05-11 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33851451-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33851451-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-33851451-icatibant-v1
- Content SHA-256: `6b77421eea9c16323cd06499735df31fa2f5211de70924074e3071b235d34057`

### Claims and source pins

#### Headline

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema. ([`pubmed-observation-pmid-33851451-2021-10-04-331647d15d89`](#source-pubmed-observation-pmid-33851451-2021-10-04-331647d15d89))

#### Summary

PubMed lists PMID 33851451 in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-05-11 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33851451-2021-10-04-331647d15d89`](#source-pubmed-observation-pmid-33851451-2021-10-04-331647d15d89))

#### Paragraph 1

PubMed lists PMID 33851451 in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-05-11 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33851451-2021-10-04-331647d15d89`](#source-pubmed-observation-pmid-33851451-2021-10-04-331647d15d89))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33851451-2021-10-04-331647d15d89`](#source-pubmed-observation-pmid-33851451-2021-10-04-331647d15d89))

### Sources

<a id="source-pubmed-observation-pmid-33851451-2021-10-04-331647d15d89"></a>
- **Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema. · retained source version 1:2021-10-04:current:331647d15d8965f147dce58aa102ac80b227b7f281bff83e4e001777d61f0aa4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33851451/) (`pubmed-observation-pmid-33851451-2021-10-04-331647d15d89`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-33851451-icatibant-v1 SHA-256: 6b77421eea9c16323cd06499735df31fa2f5211de70924074e3071b235d34057.

---

<a id="pubmed-pmid-35275476-icatibant-v1"></a>

## Exceptional treatment of COVID-19 pneumonia with icatibant.

> PubMed lists PMID 35275476 in Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias as Journal Article, with publication-date metadata of 2022-04 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35275476-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-09-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35275476-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-35275476-icatibant-v1
- Content SHA-256: `3880f6fd55a6692900eb84223f340fce0585bedfbefd1d56ee273b3342ece4bf`

### Claims and source pins

#### Headline

Exceptional treatment of COVID-19 pneumonia with icatibant. ([`pubmed-observation-pmid-35275476-2025-09-30-2b3a9bbc0ab3`](#source-pubmed-observation-pmid-35275476-2025-09-30-2b3a9bbc0ab3))

#### Summary

PubMed lists PMID 35275476 in Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias as Journal Article, with publication-date metadata of 2022-04 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35275476-2025-09-30-2b3a9bbc0ab3`](#source-pubmed-observation-pmid-35275476-2025-09-30-2b3a9bbc0ab3))

#### Paragraph 1

PubMed lists PMID 35275476 in Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias as Journal Article, with publication-date metadata of 2022-04 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35275476-2025-09-30-2b3a9bbc0ab3`](#source-pubmed-observation-pmid-35275476-2025-09-30-2b3a9bbc0ab3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35275476-2025-09-30-2b3a9bbc0ab3`](#source-pubmed-observation-pmid-35275476-2025-09-30-2b3a9bbc0ab3))

### Sources

<a id="source-pubmed-observation-pmid-35275476-2025-09-30-2b3a9bbc0ab3"></a>
- **Exceptional treatment of COVID-19 pneumonia with icatibant. · retained source version 1:2025-09-30:current:2b3a9bbc0ab39aa8f9b68d3c46c80e91334100c2357161d5721edb6218621142** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35275476/) (`pubmed-observation-pmid-35275476-2025-09-30-2b3a9bbc0ab3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exceptional treatment of COVID-19 pneumonia with icatibant." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-35275476-icatibant-v1 SHA-256: 3880f6fd55a6692900eb84223f340fce0585bedfbefd1d56ee273b3342ece4bf.

---

<a id="pubmed-pmid-35317892-icatibant-v1"></a>

## How satisfactory is on-demand icatibant from the patients' perspective in real life?

> PubMed lists PMID 35317892 in Allergy and asthma proceedings as Journal Article, with publication-date metadata of 2022-03-01 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35317892-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-04-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35317892-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-35317892-icatibant-v1
- Content SHA-256: `23df0388dbe149f7993d5e3e338d47d002487acc42121a06f0e7105a866f135d`

### Claims and source pins

#### Headline

How satisfactory is on-demand icatibant from the patients' perspective in real life? ([`pubmed-observation-pmid-35317892-2022-04-18-a2053bc25067`](#source-pubmed-observation-pmid-35317892-2022-04-18-a2053bc25067))

#### Summary

PubMed lists PMID 35317892 in Allergy and asthma proceedings as Journal Article, with publication-date metadata of 2022-03-01 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35317892-2022-04-18-a2053bc25067`](#source-pubmed-observation-pmid-35317892-2022-04-18-a2053bc25067))

#### Paragraph 1

PubMed lists PMID 35317892 in Allergy and asthma proceedings as Journal Article, with publication-date metadata of 2022-03-01 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35317892-2022-04-18-a2053bc25067`](#source-pubmed-observation-pmid-35317892-2022-04-18-a2053bc25067))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35317892-2022-04-18-a2053bc25067`](#source-pubmed-observation-pmid-35317892-2022-04-18-a2053bc25067))

### Sources

<a id="source-pubmed-observation-pmid-35317892-2022-04-18-a2053bc25067"></a>
- **How satisfactory is on-demand icatibant from the patients' perspective in real life? · retained source version 1:2022-04-18:current:a2053bc250677fa6f88698e9cdcf27570e867cfdab44b82682a8b4218049a9a6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35317892/) (`pubmed-observation-pmid-35317892-2022-04-18-a2053bc25067`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "How satisfactory is on-demand icatibant from the patients' perspective in real life?" Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-35317892-icatibant-v1 SHA-256: 23df0388dbe149f7993d5e3e338d47d002487acc42121a06f0e7105a866f135d.

---

<a id="pubmed-pmid-36641883-icatibant-v1"></a>

## In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant.

> PubMed lists PMID 36641883 in Journal of photochemistry and photobiology. B, Biology as Journal Article, with publication-date metadata of 2023-01-10 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36641883-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36641883-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-36641883-icatibant-v1
- Content SHA-256: `adff87288068e5cab6fbcc0bcfd22e064dbcf1d7d271f6302d7ff36a38213c8b`

### Claims and source pins

#### Headline

In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant. ([`pubmed-observation-pmid-36641883-2026-01-27-bf2d7f8faf9a`](#source-pubmed-observation-pmid-36641883-2026-01-27-bf2d7f8faf9a))

#### Summary

PubMed lists PMID 36641883 in Journal of photochemistry and photobiology. B, Biology as Journal Article, with publication-date metadata of 2023-01-10 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36641883-2026-01-27-bf2d7f8faf9a`](#source-pubmed-observation-pmid-36641883-2026-01-27-bf2d7f8faf9a))

#### Paragraph 1

PubMed lists PMID 36641883 in Journal of photochemistry and photobiology. B, Biology as Journal Article, with publication-date metadata of 2023-01-10 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36641883-2026-01-27-bf2d7f8faf9a`](#source-pubmed-observation-pmid-36641883-2026-01-27-bf2d7f8faf9a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36641883-2026-01-27-bf2d7f8faf9a`](#source-pubmed-observation-pmid-36641883-2026-01-27-bf2d7f8faf9a))

### Sources

<a id="source-pubmed-observation-pmid-36641883-2026-01-27-bf2d7f8faf9a"></a>
- **In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant. · retained source version 1:2026-01-27:current:bf2d7f8faf9adfa71ff8429f196cdcef05271dda4cb747d55dffedc65a20f2ce** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36641883/) (`pubmed-observation-pmid-36641883-2026-01-27-bf2d7f8faf9a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-36641883-icatibant-v1 SHA-256: adff87288068e5cab6fbcc0bcfd22e064dbcf1d7d271f6302d7ff36a38213c8b.

---

<a id="pubmed-pmid-37067851-icatibant-v1"></a>

## Icatibant in viral infections.

> PubMed lists PMID 37067851 in Infectious diseases (London, England) as Letter, Comment, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37067851-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37067851-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-37067851-icatibant-v1
- Content SHA-256: `b4e11534dc9e32ee84f5e187f9186c5905c586a674d5cc3386cd56e5bba04011`

### Claims and source pins

#### Headline

Icatibant in viral infections. ([`pubmed-observation-pmid-37067851-2026-01-27-0019f66a21e3`](#source-pubmed-observation-pmid-37067851-2026-01-27-0019f66a21e3))

#### Summary

PubMed lists PMID 37067851 in Infectious diseases (London, England) as Letter, Comment, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37067851-2026-01-27-0019f66a21e3`](#source-pubmed-observation-pmid-37067851-2026-01-27-0019f66a21e3))

#### Paragraph 1

PubMed lists PMID 37067851 in Infectious diseases (London, England) as Letter, Comment, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37067851-2026-01-27-0019f66a21e3`](#source-pubmed-observation-pmid-37067851-2026-01-27-0019f66a21e3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37067851-2026-01-27-0019f66a21e3`](#source-pubmed-observation-pmid-37067851-2026-01-27-0019f66a21e3))

### Sources

<a id="source-pubmed-observation-pmid-37067851-2026-01-27-0019f66a21e3"></a>
- **Icatibant in viral infections. · retained source version 1:2026-01-27:current:0019f66a21e3f34e79e7772a19d49d9f5396c9c2658a96296b46b9160cb1f52c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37067851/) (`pubmed-observation-pmid-37067851-2026-01-27-0019f66a21e3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant in viral infections." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-37067851-icatibant-v1 SHA-256: b4e11534dc9e32ee84f5e187f9186c5905c586a674d5cc3386cd56e5bba04011.

---

<a id="pubmed-pmid-38142950-icatibant-v1"></a>

## Assessing the performance of new chromatographic technologies for the separation of peptide epimeric impurities: the case of Icatibant.

> PubMed lists PMID 38142950 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, with publication-date metadata of 2023-12-22 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38142950-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38142950-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-38142950-icatibant-v1
- Content SHA-256: `b4264052697582efe427db167ef0b6807d4603f67e7be533ad59d4eeec921f0b`

### Claims and source pins

#### Headline

Assessing the performance of new chromatographic technologies for the separation of peptide epimeric impurities: the case of Icatibant. ([`pubmed-observation-pmid-38142950-2026-01-27-f5d2672805a1`](#source-pubmed-observation-pmid-38142950-2026-01-27-f5d2672805a1))

#### Summary

PubMed lists PMID 38142950 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, with publication-date metadata of 2023-12-22 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38142950-2026-01-27-f5d2672805a1`](#source-pubmed-observation-pmid-38142950-2026-01-27-f5d2672805a1))

#### Paragraph 1

PubMed lists PMID 38142950 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, with publication-date metadata of 2023-12-22 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38142950-2026-01-27-f5d2672805a1`](#source-pubmed-observation-pmid-38142950-2026-01-27-f5d2672805a1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38142950-2026-01-27-f5d2672805a1`](#source-pubmed-observation-pmid-38142950-2026-01-27-f5d2672805a1))

### Sources

<a id="source-pubmed-observation-pmid-38142950-2026-01-27-f5d2672805a1"></a>
- **Assessing the performance of new chromatographic technologies for the separation of peptide epimeric impurities: the case of Icatibant. · retained source version 1:2026-01-27:current:f5d2672805a1460c79b737f4a827059921b456fd8ecd9bec85522be1732821af** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38142950/) (`pubmed-observation-pmid-38142950-2026-01-27-f5d2672805a1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Assessing the performance of new chromatographic technologies for the separation of peptide epimeric impurities: the case of Icatibant." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-38142950-icatibant-v1 SHA-256: b4264052697582efe427db167ef0b6807d4603f67e7be533ad59d4eeec921f0b.

---

<a id="pubmed-pmid-40559541-icatibant-v1"></a>

## Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant.

> PubMed lists PMID 40559541 in Pathogens (Basel, Switzerland) as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2025-05-27 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40559541-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40559541-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-40559541-icatibant-v1
- Content SHA-256: `f5e3bb3982d0b61044e5ec3ed377b0e013aeaee07dde8da76161349f04a5421a`

### Claims and source pins

#### Headline

Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant. ([`pubmed-observation-pmid-40559541-2025-06-27-faaafa5babc0`](#source-pubmed-observation-pmid-40559541-2025-06-27-faaafa5babc0))

#### Summary

PubMed lists PMID 40559541 in Pathogens (Basel, Switzerland) as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2025-05-27 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40559541-2025-06-27-faaafa5babc0`](#source-pubmed-observation-pmid-40559541-2025-06-27-faaafa5babc0))

#### Paragraph 1

PubMed lists PMID 40559541 in Pathogens (Basel, Switzerland) as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2025-05-27 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40559541-2025-06-27-faaafa5babc0`](#source-pubmed-observation-pmid-40559541-2025-06-27-faaafa5babc0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40559541-2025-06-27-faaafa5babc0`](#source-pubmed-observation-pmid-40559541-2025-06-27-faaafa5babc0))

### Sources

<a id="source-pubmed-observation-pmid-40559541-2025-06-27-faaafa5babc0"></a>
- **Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant. · retained source version 1:2025-06-27:current:faaafa5babc09af860e131d946bd26009d372116b3e0808c00e907998ea87ec8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40559541/) (`pubmed-observation-pmid-40559541-2025-06-27-faaafa5babc0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-40559541-icatibant-v1 SHA-256: f5e3bb3982d0b61044e5ec3ed377b0e013aeaee07dde8da76161349f04a5421a.

---

<a id="pubmed-pmid-41008531-icatibant-v1"></a>

## Icatibant Acts as a Balanced Ligand of MRGPRX2 in Human Skin Mast Cells.

> PubMed lists PMID 41008531 in Biomolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-25 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41008531-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41008531-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-41008531-icatibant-v1
- Content SHA-256: `847c07a72ffb31c6784246c100c8ed9a2c060405cfac48bc514f26697b54990a`

### Claims and source pins

#### Headline

Icatibant Acts as a Balanced Ligand of MRGPRX2 in Human Skin Mast Cells. ([`pubmed-observation-pmid-41008531-2026-03-29-718814e022fe`](#source-pubmed-observation-pmid-41008531-2026-03-29-718814e022fe))

#### Summary

PubMed lists PMID 41008531 in Biomolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-25 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41008531-2026-03-29-718814e022fe`](#source-pubmed-observation-pmid-41008531-2026-03-29-718814e022fe))

#### Paragraph 1

PubMed lists PMID 41008531 in Biomolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-25 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41008531-2026-03-29-718814e022fe`](#source-pubmed-observation-pmid-41008531-2026-03-29-718814e022fe))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41008531-2026-03-29-718814e022fe`](#source-pubmed-observation-pmid-41008531-2026-03-29-718814e022fe))

### Sources

<a id="source-pubmed-observation-pmid-41008531-2026-03-29-718814e022fe"></a>
- **Icatibant Acts as a Balanced Ligand of MRGPRX2 in Human Skin Mast Cells. · retained source version 1:2026-03-29:current:718814e022fe155d5bc3338ae230375fd963a3752e8ee336011e9750a2622d3c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41008531/) (`pubmed-observation-pmid-41008531-2026-03-29-718814e022fe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant Acts as a Balanced Ligand of MRGPRX2 in Human Skin Mast Cells." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-41008531-icatibant-v1 SHA-256: 847c07a72ffb31c6784246c100c8ed9a2c060405cfac48bc514f26697b54990a.

---

<a id="pubmed-pmid-41133754-icatibant-v1"></a>

## Icatibant Use During Pregnancy: A South African Case Series.

> PubMed lists PMID 41133754 in Journal of investigational allergology & clinical immunology as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41133754-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-12-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41133754-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-41133754-icatibant-v1
- Content SHA-256: `d2d3cc1d66fc68256bcea7e6e9b648cef6a458200317153063b7777feb7cbd71`

### Claims and source pins

#### Headline

Icatibant Use During Pregnancy: A South African Case Series. ([`pubmed-observation-pmid-41133754-2025-12-16-b3374388215a`](#source-pubmed-observation-pmid-41133754-2025-12-16-b3374388215a))

#### Summary

PubMed lists PMID 41133754 in Journal of investigational allergology & clinical immunology as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41133754-2025-12-16-b3374388215a`](#source-pubmed-observation-pmid-41133754-2025-12-16-b3374388215a))

#### Paragraph 1

PubMed lists PMID 41133754 in Journal of investigational allergology & clinical immunology as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41133754-2025-12-16-b3374388215a`](#source-pubmed-observation-pmid-41133754-2025-12-16-b3374388215a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41133754-2025-12-16-b3374388215a`](#source-pubmed-observation-pmid-41133754-2025-12-16-b3374388215a))

### Sources

<a id="source-pubmed-observation-pmid-41133754-2025-12-16-b3374388215a"></a>
- **Icatibant Use During Pregnancy: A South African Case Series. · retained source version 1:2025-12-16:current:b3374388215a9bc82bbb5b104122acb9d21b4b6d365e4addb648b402505e3553** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41133754/) (`pubmed-observation-pmid-41133754-2025-12-16-b3374388215a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant Use During Pregnancy: A South African Case Series." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-41133754-icatibant-v1 SHA-256: d2d3cc1d66fc68256bcea7e6e9b648cef6a458200317153063b7777feb7cbd71.

---

<a id="pubmed-pmid-42219034-icatibant-v1"></a>

## First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib.

> PubMed lists PMID 42219034 in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases as Journal Article, Case Reports, with publication-date metadata of 2026-05-30 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42219034-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42219034-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-42219034-icatibant-v1
- Content SHA-256: `cc24d411b750f026306b7fb43eeac0de25912aa089747ca58078865bc900d424`

### Claims and source pins

#### Headline

First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib. ([`pubmed-observation-pmid-42219034-2026-07-20-4a13c722e208`](#source-pubmed-observation-pmid-42219034-2026-07-20-4a13c722e208))

#### Summary

PubMed lists PMID 42219034 in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases as Journal Article, Case Reports, with publication-date metadata of 2026-05-30 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42219034-2026-07-20-4a13c722e208`](#source-pubmed-observation-pmid-42219034-2026-07-20-4a13c722e208))

#### Paragraph 1

PubMed lists PMID 42219034 in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases as Journal Article, Case Reports, with publication-date metadata of 2026-05-30 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42219034-2026-07-20-4a13c722e208`](#source-pubmed-observation-pmid-42219034-2026-07-20-4a13c722e208))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42219034-2026-07-20-4a13c722e208`](#source-pubmed-observation-pmid-42219034-2026-07-20-4a13c722e208))

### Sources

<a id="source-pubmed-observation-pmid-42219034-2026-07-20-4a13c722e208"></a>
- **First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib. · retained source version 1:2026-07-20:current:4a13c722e2089eb988f66162128597ba40ed08927e74817cceaa4bb12072a5ec** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42219034/) (`pubmed-observation-pmid-42219034-2026-07-20-4a13c722e208`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-42219034-icatibant-v1 SHA-256: cc24d411b750f026306b7fb43eeac0de25912aa089747ca58078865bc900d424.

---

<a id="pubmed-pmid-42343494-icatibant-v1"></a>

## Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review.

> PubMed lists PMID 42343494 in Allergy and asthma proceedings as Journal Article, Systematic Review, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42343494-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42343494-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-42343494-icatibant-v1
- Content SHA-256: `b0a09ea599db07f046d2f2b24592606f6499e49be790cb1babe00591e81b86a4`

### Claims and source pins

#### Headline

Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review. ([`pubmed-observation-pmid-42343494-2026-06-30-96fe90b6eb8e`](#source-pubmed-observation-pmid-42343494-2026-06-30-96fe90b6eb8e))

#### Summary

PubMed lists PMID 42343494 in Allergy and asthma proceedings as Journal Article, Systematic Review, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42343494-2026-06-30-96fe90b6eb8e`](#source-pubmed-observation-pmid-42343494-2026-06-30-96fe90b6eb8e))

#### Paragraph 1

PubMed lists PMID 42343494 in Allergy and asthma proceedings as Journal Article, Systematic Review, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42343494-2026-06-30-96fe90b6eb8e`](#source-pubmed-observation-pmid-42343494-2026-06-30-96fe90b6eb8e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42343494-2026-06-30-96fe90b6eb8e`](#source-pubmed-observation-pmid-42343494-2026-06-30-96fe90b6eb8e))

### Sources

<a id="source-pubmed-observation-pmid-42343494-2026-06-30-96fe90b6eb8e"></a>
- **Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review. · retained source version 1:2026-06-30:current:96fe90b6eb8e95b837424210109fd6e61191ab01a9f82939abd5af48fe01ed3b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42343494/) (`pubmed-observation-pmid-42343494-2026-06-30-96fe90b6eb8e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-42343494-icatibant-v1 SHA-256: b0a09ea599db07f046d2f2b24592606f6499e49be790cb1babe00591e81b86a4.

---

<a id="pubmed-pmid-42656409-icatibant-v1"></a>

## On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation.

> PubMed lists PMID 42656409 in Genes & diseases as Editorial, with publication-date metadata of 2026-05-14 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42656409-icatibant:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42656409-icatibant/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-42656409-icatibant-v1
- Content SHA-256: `ec67b9c46dcfa2dba1df285a36e77eebf01dd001ec12689177c411dd0c65ad3c`

### Claims and source pins

#### Headline

On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation. ([`pubmed-observation-pmid-42656409-2026-08-28-329cb8784485`](#source-pubmed-observation-pmid-42656409-2026-08-28-329cb8784485))

#### Summary

PubMed lists PMID 42656409 in Genes & diseases as Editorial, with publication-date metadata of 2026-05-14 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42656409-2026-08-28-329cb8784485`](#source-pubmed-observation-pmid-42656409-2026-08-28-329cb8784485))

#### Paragraph 1

PubMed lists PMID 42656409 in Genes & diseases as Editorial, with publication-date metadata of 2026-05-14 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42656409-2026-08-28-329cb8784485`](#source-pubmed-observation-pmid-42656409-2026-08-28-329cb8784485))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42656409-2026-08-28-329cb8784485`](#source-pubmed-observation-pmid-42656409-2026-08-28-329cb8784485))

### Sources

<a id="source-pubmed-observation-pmid-42656409-2026-08-28-329cb8784485"></a>
- **On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation. · retained source version 1:2026-08-28:current:329cb878448588e6d2bb0bf5e340473ff0c96cd854bf108c1d6a53d084a8f85f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42656409/) (`pubmed-observation-pmid-42656409-2026-08-28-329cb8784485`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/icatibant.json#pubmed-pmid-42656409-icatibant-v1 SHA-256: ec67b9c46dcfa2dba1df285a36e77eebf01dd001ec12689177c411dd0c65ad3c.

